

Prof. CAVİT BOZ

Personal Information

Office Phone: [+90 462 377 1115](tel:+904623771115)

Office Phone: [+90 462 377 1037](tel:+904623771037)

Fax Phone: [+90 0533 356 2836](tel:+9005333562836)

Email: cboz@ktu.edu.tr

Web: <https://avesis.ktu.edu.tr//cboz>

International Researcher IDs

ScholarID: Cavit

ORCID: 0000-0003-0956-3304

Publons / Web Of Science ResearcherID: V-5127-2017

ScopusID: 6701728553

Yoksis Researcher ID: 8354

Education Information

Expertise In Medicine, Karadeniz Technical University, Nöroloji, Turkey 1995 - 2000

Undergraduate, Karadeniz Technical University, Tıp Fakültesi, Turkey 1988 - 1994

Foreign Languages

French, B1 Intermediate

English, B2 Upper Intermediate

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Neurology

Academic Titles / Tasks

Professor, Karadeniz Technical University, Tıp Fakültesi, Dahili Tıp, 2000 - Continues

Jury Memberships

Associate Professor Exam, DOçentlik sınavı, EGE Üniversitesi, October, 2015

Published journal articles indexed by SCI, SSCI, and AHCI

- Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies**

Yeh W. Z., van der Walt A., Skibina O. G., Kalincik T., Alroughani R., Kermodé A. G., Fabis-Pedrini M. J., Carroll W. M.,

Lechner-Scott J, BOZ C., et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, vol.11, no.6, 2024 (SCI-Expanded)

- II. **Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60**
Foong Y. C., Merlo D., Gresle M., Buzzard K., Zhong M., Yeh W. Z., Jokubaitis V., Monif M., Skibina O., Ozakbas S., et al.
Journal of Neurology, Neurosurgery and Psychiatry, vol.95, no.8, pp.767-774, 2024 (SCI-Expanded)
- III. **Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein**
KOÇ S., ŞEN S., TERZİ Y., KIZILAY F., DEMİR S., AKSOY D. B., KURTULUŞ F., BİLGE N., İDİLMAN E., UZUNKÖPRÜ C., et al.
Balkan Medical Journal, vol.41, no.4, pp.272-279, 2024 (SCI-Expanded)
- IV. **Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study**
Dekeyser C., Hautekeete M., Cambron M., Van Pesch V., Patti F., Kuhle J., Khoury S., Scott J. L., Gerlach O., Lugaresi A., et al.
Journal of Neurology, Neurosurgery and Psychiatry, 2024 (SCI-Expanded)
- V. **Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis**
Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, Alroughani R, Eichau Madueño S, BOZ C, van der Walt A., et al.
Multiple Sclerosis Journal, 2024 (SCI-Expanded)
- VI. **Risk of secondary progressive multiple sclerosis after early worsening of disability**
Dzau W., Sharmin S, Patti F, Izquierdo G, Eichau S, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A., et al.
Journal of Neurology, Neurosurgery and Psychiatry, vol.94, no.12, pp.984-991, 2023 (SCI-Expanded)
- VII. **The risk of secondary progressive multiple sclerosis is geographically determined but modifiable**
Sharmin S, Roos I, Simpson-Yap S, Malpas C, Sánchez M. M., Ozakbas S, Horakova D, Havrdova E. K., Patti F, Alroughani R., et al.
Brain : a journal of neurology, vol.146, no.11, pp.4633-4644, 2023 (SCI-Expanded)
- VIII. **Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting**
Altunan B, Ünal A, EFENDİ H, Köseoğlu M, Terzi M, Kotan D, Tamam Y, BOZ C, GÜLER S, TURAN Ö. F., et al.
Multiple Sclerosis and Related Disorders, vol.77, 2023 (SCI-Expanded)
- IX. **Disability accrual in primary and secondary progressive multiple sclerosis**
Harding-Forrester S, Roos I, Nguyen A, Malpas C. B., Diouf I, Moradi N, Sharmin S, Izquierdo G, Eichau S, Patti F, et al.
Journal of Neurology, Neurosurgery and Psychiatry, vol.94, no.9, pp.707-717, 2023 (SCI-Expanded)
- X. **mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?**
Tütüncü M., Demir S, Arslan G, Dinç Ö, Şen S, GÜNDÜZ T, Uzunköprü C, Gümüş H, Tütüncü M, Akçin R., et al.
Multiple Sclerosis and Related Disorders, vol.75, 2023 (SCI-Expanded)
- XI. **The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis**
BOZ C., ÖZAKBAŞ S., Terzi M., KARABUDAK R., Sevim S., Turkoglu R., Soysal A., Balci B. P., EFENDİ H., TURAN Ö. F., et al.
Neurological Sciences, vol.44, no.6, pp.2121-2129, 2023 (SCI-Expanded)
- XII. **Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment**
Terzi M., Helvacı E. M., Şen S, BOZ C., Çilingir V., Akçali A., Beckmann Y., Uzunköprü C., Türkoğlu R., Yüceyar N., et al.
Noropsikiyatri Arsivi, vol.60, no.1, pp.23-27, 2023 (SCI-Expanded)
- XIII. **External validation of a clinical prediction model in multiple sclerosis**
Moradi N, Sharmin S, Malpas C. B., Shaygannejad V., Terzi M., BOZ C., Yamout B., Khoury S. J., Turkoglu R.,

KARABUDAK R., et al.

Multiple Sclerosis Journal, vol.29, no.2, pp.261-269, 2023 (SCI-Expanded)

- XIV. **The Effect of Smoking on Inactivated and mRNA Vaccine Responses Applied to Prevent COVID-19 in Multiple Sclerosis**
Şen S., Arslan G., Tütüncü M., Demir S., Dinç Ö., GÜNDÜZ T., Uzunköprü C., Gümüş H., Tütüncü M., Akçin R., et al.
Noropsikiyatri Arsivi, vol.60, no.3, pp.252-256, 2023 (SCI-Expanded)
- XV. **Clinical course and outcome of Covid-19 in patients with myasthenia gravis**
Aktöz G., BOZ C., Zengin S., Okumus A. C., Horozoglu H., KARA F., Oral E., Ozmenoglu M.
Neurological Research, vol.45, no.6, pp.583-589, 2023 (SCI-Expanded)
- XVI. **Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)**
Tuncer A., Kürtüncü M., Terzi M., UYGUNOĞLU U., Göncüoğlu C., Yüceyar A. N., Ekmekçi Ö., Türkoğlu R., Soysal A., Köseoğlu M., et al.
Turkish Journal of Medical Sciences, vol.53, no.1, pp.323-332, 2023 (SCI-Expanded)
- XVII. **Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis**
Usta N. C., BOZ C., Terzi M.
Clinical Neurology and Neurosurgery, vol.224, 2023 (SCI-Expanded)
- XVIII. **Evaluation of clinical features and prognosis of myasthenia gravis in adults based on the age of onset: A retrospective study from a single center of 30 years MG registry**
KARA F., GÖL M. F., BOZ C.
Neurology Asia, vol.27, no.4, pp.981-989, 2022 (SCI-Expanded)
- XIX. **Updated Results of the COVID-19 in MS Global Data Sharing Initiative Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity**
Simpson-Yap S., Pirmani A., Kalincik T., De Brouwer E., Geys L., Parciak T., Helme A., Rijke N., Hillert J. A., Moreau Y., et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, vol.9, no.6, 2022 (SCI-Expanded)
- XX. **Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis**
Zhu C., Zhou Z., Roos I., Merlo D., Kalincik T., ÖZAKBAŞ S., Skibina O., Kuhle J., Hodgkinson S., Boz C., et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol.93, pp.1330-1337, 2022 (SCI-Expanded)
- XXI. **Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β**
Simpson-Yap S., Pirmani A., De Brouwer E., Peeters L. M., Geys L., Parciak T., Helme A., Hillert J., Moreau Y., Edan G., et al.
Multiple Sclerosis and Related Disorders, vol.66, 2022 (SCI-Expanded)
- XXII. **Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis**
Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E. K., Debouverie M., Patti F., De Seze J., Izquierdo G., et al.
NEUROLOGY, vol.99, no.17, 2022 (SCI-Expanded)
- XXIII. **Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS**
Kalincik T., Kister I., Bacon T. E., Malpas C. B., Sharmin S., Horakova D., Kubala-Havrdova E., Patti F., Izquierdo G., Eichau S., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.28, no.11, pp.1752-1761, 2022 (SCI-Expanded)
- XXIV. **Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry**
Sharmin S., Malpas C. B., Roos I., Diouf I., Alroughani R., ÖZAKBAŞ S., Izquierdo G., Eichau S., Horakova D., Havrdova E. K., et al.
Journal of Neurology, Neurosurgery and Psychiatry, vol.93, no.12, pp.1322-1329, 2022 (SCI-Expanded)
- XXV. **Confirmed disability progression as a marker of permanent disability in multiple sclerosis**
Sharmin S., Bovis F., Malpas C., Horakova D., Havrdova E. K., Izquierdo G., Eichau S., Trojano M., Prat A., Girard M., et al.
EUROPEAN JOURNAL OF NEUROLOGY, vol.29, no.8, pp.2321-2334, 2022 (SCI-Expanded)

- XXVI. **Disease activity during pregnancy and postpartum in women with MS receiving ocrelizumab in a real-world cohort**
Yeh W., Van der Walt A., Kermode A., Kalincik T., Alroughani R., Lechner-Scott J., BOZ C., Butler E., Buzzard K., Skibina O., et al.
EUROPEAN JOURNAL OF NEUROLOGY, vol.29, pp.295-296, 2022 (SCI-Expanded)
- XXVII. **Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study**
Vitkova M., Diouf I., Malpas C., Horakova D., Havrdova E. K., Patti F., ÖZAKBAŞ S., Izquierdo G., Eichau S., Shaygannejad V., et al.
NEUROLOGY, vol.98, no.24, 2022 (SCI-Expanded)
- XXVIII. **Prediction of multiple sclerosis outcomes when switching to ocrelizumab**
Zhong M., van der Walt A., Stankovich J., Kalincik T., Buzzard K., Skibina O., BOZ C., Hodgkinson S., Slee M., Lechner-Scott J., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.28, no.6, pp.958-969, 2022 (SCI-Expanded)
- XXIX. **Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis**
Lefort M., Sharmin S., Andersen J. B., Vukusic S., Casey R., Debouverie M., Edan G., Ciron J., Ruet A., De Seze J., et al.
BMC MEDICAL RESEARCH METHODOLOGY, vol.22, no.1, 2022 (SCI-Expanded)
- XXX. **Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom**
Herring W. L., Zhang Y., Tempest M., Pearson I., Freudensprung U., Acosta C., Dort T., Hyde R., Horakova D., Trojano M., et al.
PharmacoEconomics, vol.40, no.3, pp.323-339, 2022 (SCI-Expanded)
- XXXI. **Neurological manifestations and etiological risk factors in patients hospitalized with COVID-19 in Turkey**
Usta N. C., Kartal S., Gunay B. O., BOZ C.
Asian Biomedicine, vol.16, no.1, pp.23-30, 2022 (SCI-Expanded)
- XXXII. **EFFECTS OF RITUXIMAB ON PROGNOSIS IN MYASTHENIA GRAVIS: A SINGLE-CENTER EXPERIENCE FROM TURKEY**
GÖL M. F., KARA F., BOZ M., MUTLU A., Karakullukçu S., BOZ C.
Ideggyogyaszati Szemle, vol.75, no.9-10, pp.351-359, 2022 (SCI-Expanded)
- XXXIII. **Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression**
Sevim S., DEMİRKIRAN D. M., Terzi M., YÜCEYAR A. N., Tasdelen B., Idiman E., KÜRTÜNCÜ M., BOZ C., Tuncel D., KARABUDAK R., et al.
ARQUIVOS DE NEURO-PSIQUIATRIA, vol.80, pp.168-172, 2022 (SCI-Expanded)
- XXXIV. **Neuropathic Pain Frequency in Neurology Outpatients: A Multicenter Study**
Bekircan-Kurt C. E., Inan B., Bulut O., Sengun I., KARLI H. N., Gunes N., Cokal B. G., Keskin Guler S., Yoldas T. K., Guner Ozcanyuz D., et al.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.58, no.4, pp.257-260, 2021 (SCI-Expanded)
- XXXV. **Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry**
Kenney R., Liu M., Patil S., Alroughani R., Ampapa R., Bergamaschi R., BOZ C., Butzkueven H., Gomez J. C., Cartechini E., et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES, vol.430, 2021 (SCI-Expanded)
- XXXVI. **Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts**
Sharmin S., Lefort M., Andersen J. B., Leray E., Horakova D., Havrdova E. K., Alroughani R., Izquierdo G., ÖZAKBAŞ S., Patti F., et al.
CNS DRUGS, vol.35, no.11, pp.1217-1232, 2021 (SCI-Expanded)
- XXXVII. **Determinants of therapeutic lag in multiple sclerosis**
Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., Havrdova E. K., Debouverie M., Trojano M., Patti

- F., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.27, no.12, pp.1838-1851, 2021 (SCI-Expanded)
- XXXVIII. **Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018**
Moradi N., Sharmin S., Malpas C., ÖZAKBAŞ S., Shaygannejad V., Terzi M., BOZ C., Yamout B., Turkoglu R., KARABUDAK R., et al.
CNS DRUGS, vol.35, no.10, pp.1097-1106, 2021 (SCI-Expanded)
- XXXIX. **Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression**
De Brouwer E., Becker T., Moreau Y., Havrdova E. K., Trojano M., Eichau S., ÖZAKBAŞ S., Onofrij M., Grammond P., Kuhle J., et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, vol.208, 2021 (SCI-Expanded)
- XL. **The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies**
Andersen J. B., Sharmin S., Lefort M., Koch-Henriksen N., Sellebjerg F., Sorensen P. S., Christensen C. C. H., Rasmussen P., Jensen M. B., Frederiksen J. L., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.53, 2021 (SCI-Expanded)
- XLII. **Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis**
Yeh W. Z., Widyastuti P. A., Van der Walt A., Stankovich J., Havrdova E., Horakova D., Vodehnalova K., ÖZAKBAŞ S., Eichau S., Duquette P., et al.
NEUROLOGY, vol.96, no.24, 2021 (SCI-Expanded)
- XLIII. **Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis**
Minh Le M. L., Malpas C., Sharmin S., Horakova D., Havrdova E., Trojano M., Izquierdo G., Eichau S., ÖZAKBAŞ S., Lugaresi A., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.27, no.5, pp.755-766, 2021 (SCI-Expanded)
- XLIV. **Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score**
Kunchok A., Lechner-Scott J., Granella F., Trojano M., Alroughani R., Sola P., Ferraro D., Lugaresi A., Onofrij M., ÖZAKBAŞ S., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.27, no.5, pp.695-705, 2021 (SCI-Expanded)
- XLV. **Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years**
Kalincik T., Diouf I., Sharmin S., Malpas C., Spelman T., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., Lugaresi A., et al.
NEUROLOGY, vol.96, no.5, 2021 (SCI-Expanded)
- XLVI. **Determinants of disability development in patients with multiple sclerosis**
KARA F., GÖL M. F., BOZ C.
ARQUIVOS DE NEURO-PSIQUIATRIA, vol.79, no.6, pp.489-496, 2021 (SCI-Expanded)
- XLVII. **The Role of Thrombo-inflammatory Biomarkers in the Prognosis of Cere-bral Venous Sinus Thrombosis**
Karahan S. Z., GAZİOĞLU S., DİLAVER İ., BOZ C.
CURRENT NEUROVASCULAR RESEARCH, vol.18, no.2, pp.237-243, 2021 (SCI-Expanded)
- XLVIII. **Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a**
Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., Havrdova E. K., Trojano M., Prat A., Girard M., et al.
NEUROLOGY, vol.96, no.2, 2021 (SCI-Expanded)
- XLIX. **Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study**
Barnett M., Bergsland N., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., Gaillard F., van Pesch V., ÖZAKBAŞ S., Ignacio Rojas J., et al.
NEUROIMAGE-CLINICAL, vol.32, 2021 (SCI-Expanded)
- L. **Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis**
Lizak N., Malpas C. B., Sharmin S., Havrdova E. K., Horakova D., Izquierdo G., Eichau S., Lugaresi A., Duquette P.,

Girard M., et al.

JAMA NEUROLOGY, vol.77, no.11, pp.1398-1407, 2020 (SCI-Expanded)

- L. **Methylprednisolone Concentrations in Breast Milk and Serum of Patients with Multiple Sclerosis Treated with IV Pulse Methylprednisolone**
Karahan S. Z., BOZ C., Terzi M., Aktoz G., Sen S., Ozbudun B., Caglar A., Sener M.
CLINICAL NEUROLOGY AND NEUROSURGERY, vol.197, 2020 (SCI-Expanded)
- LI. **Delay from treatment start to full effect of immunotherapies for multiple sclerosis**
Roos I., Leray E., Frascoli F., Casey R., Brown J. W. L., Horakova D., Havrdova E. K., Trojano M., Patti F., Izquierdo G., et al.
BRAIN, vol.143, pp.2742-2756, 2020 (SCI-Expanded)
- LII. **Revisiting the complex architecture of ALS in Turkey: Expanding genotypes, shared phenotypes, molecular networks, and a public variant database**
Tunca C., Seker T., Akcimen F., Coskun C., Bayraktar E., Palvadeau R., Zor S., Kocoglu C., Kartal E., Sen N. E., et al.
HUMAN MUTATION, vol.41, no.8, 2020 (SCI-Expanded)
- LIII. **'Is RLS a harbinger and consequence of MS?: Striking results of the 'RELOMS-T' study'**
Sevim S., DEMİRKIRAN D. M., Terzi M., YÜCEYAR A. N., Tasdelen B., Idiman E., KÜRTÜNCÜ M., BOZ C., Tuncel D., KARABUDAK R., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.42, 2020 (SCI-Expanded)
- LIV. **Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review**
AlSharoqi I. A., Aljumah M., Bohlega S., BOZ C., Daif A., El-Koussa S., Inshasi J., Kurtuncu M., Mueller T., Retief C., et al.
NEUROLOGY AND THERAPY, vol.9, no.1, pp.55-66, 2020 (SCI-Expanded)
- LV. **Early clinical markers of aggressive multiple sclerosis**
Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., Eichau S., Bergamaschi R., et al.
BRAIN, vol.143, pp.1400-1413, 2020 (SCI-Expanded)
- LVI. **Decreased second to fourth digit ratios in female multiple sclerosis patients**
GAZİOĞLU S., ALKAN İ., KARAMAN A. G., BOZ C.
EARLY HUMAN DEVELOPMENT, vol.144, 2020 (SCI-Expanded)
- LVII. **Electrophysiological, functional and histopathological assessments of high dose melatonin on regeneration after blunt sciatic nerve injury**
Yazar U., Çakır E., Boz C., Çobanoğlu Ü., Baykal S.
JOURNAL OF CLINICAL NEUROSCIENCE, vol.72, pp.370-377, 2020 (SCI-Expanded)
- LVIII. **Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder**
Kunchok A., Malpas C., Nytrova P., Havrdova E. K., Alroughani R., TERZİ M., Yamout B., Hor J. Y., KARABUDAK R., BOZ C., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.38, 2020 (SCI-Expanded)
- LIX. **Risk of secondary progressive multiple sclerosis: A longitudinal study**
Fambiatos A., Jokubaitis V., Horakova D., Havrdova E. K., Trojano M., Prat A., Girard M., Duquette P., Lugaresi A., Izquierdo G., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.26, no.1, pp.79-90, 2020 (SCI-Expanded)
- LX. **A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial**
Akman Demir G., Turkoglu R., Saip S., Yuceyar N., EFENDİ H., TURAN Ö. F., AĞAN YILDIRIM K., TERZİ M., BOZ C., Tuncer A., et al.
NOROSPIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.56, no.4, pp.253-257, 2019 (SCI-Expanded)
- LXI. **International consensus on quality standards for brain health-focused care in multiple sclerosis**
Hobart J., Bowen A., Pepper G., Crofts H., Eberhard L., Berger T., Boyko A., BOZ C., Butzkueven H., Celius E. G., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.25, no.13, pp.1809-1818, 2019 (SCI-Expanded)
- LXII. **Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis**

- BOZ C., TERZI M., Ozer B., Turkoglu R., KARABUDAK R., EFENDI H., Soysal A., Sevim S., Altintas A., Kurne A., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.36, 2019 (SCI-Expanded)
- LXIII. **Susac Syndrome: Clinical characteristics, diagnostic findings and treatment in 19 cases**
Karahan S. Z., Boz C., Saip S., Kale N., Demirkaya S., Celik Y., Demir S., Kurne A., Ozbek S. E., Terzi M.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.33, pp.94-99, 2019 (SCI-Expanded)
- LXIV. **Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis**
Kalincik T., Havrdova E. K., Horakova D., Izquierdo G., Prat A., Girard M., Duquette P., Grammond P., Onofrij M., Lugaresi A., et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol.90, no.4, pp.458-468, 2019 (SCI-Expanded)
- LXV. **Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study**
Nguyen A., Havrdova E. K., Horakova D., Izquierdo G., Kalincik T., van der Walt A., TERZI M., Alroughani R., Duquette P., Girard M., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.28, pp.235-243, 2019 (SCI-Expanded)
- LXVI. **Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis**
Brown J. W. L., Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., Girard M., Duquette P., Trojano M., Lugaresi A., et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol.321, no.2, pp.175-187, 2019 (SCI-Expanded)
- LXVII. **Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis**
Hughes J., Jokubaitis V., Lugaresi A., Hupperts R., Izquierdo G., Prat A., Girard M., Duquette P., Grand'Maison F., Grammond P., et al.
JAMA NEUROLOGY, vol.75, no.11, pp.1407-1415, 2018 (SCI-Expanded)
- LXVIII. **Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis**
Min M., Spelman T., Lugaresi A., BOZ C., Spitaleri D. L. A., Pucci E., Grand'Maison F., Granella F., Izquierdo G., Butzkueven H., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.24, no.12, pp.1569-1577, 2018 (SCI-Expanded)
- LXIX. **Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy**
Kister I., Spelman T., Patti F., Duquette P., Trojano M., Izquierdo G., Lugaresi A., Grammond P., Sola P., Ferraro D., et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES, vol.391, pp.72-76, 2018 (SCI-Expanded)
- LXX. **Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis**
BOZ C., TERZI M., Karahan S. Z., Sen S., Sarac Y., Mavis M. E.
MULTIPLE SCLEROSIS JOURNAL, vol.24, no.9, pp.1205-1211, 2018 (SCI-Expanded)
- LXXI. **Reply to: Comment on YD Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]**
Fragoso Y. D., Brooks J. B. B., Spelman T., BOZ C., Alroughani R., Lugaresi A., Vucic S., Butzkueven H., TERZI M., Havrdova E., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.22, pp.166, 2018 (SCI-Expanded)
- LXXII. **Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis**
Signori A., Izquierdo G., Lugaresi A., Hupperts R., Grand'Maison F., Sola P., Horakova D., Havrdova E., Prat A., Girard M., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.24, no.5, pp.642-652, 2018 (SCI-Expanded)
- LXXIII. **Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study**
Kappos L., Bar-Or A., Cree B. A. C., Fox R. J., Giovannoni G., Gold R., Vermersch P., Arnold D. L., Arnould S., Scherz T., et al.
The Lancet, vol.391, no.10127, pp.1263-1273, 2018 (SCI-Expanded)

- LXXIV. **Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod**
Fragoso Y. D., Spelman T., BOZ C., Alroughani R., Lugaresi A., Vucic S., Butzkueven H., TERZI M., Havrdova E., Horakova D., et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.19, pp.105-108, 2018 (SCI-Expanded)
- LXXV. **Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study**
Howard J. F., Utsugisawa K., Benatar M., Murai H., Barohn R. J., Illa I., Jacob S., Vissing J., Burns T. M., Kissel J. T., et al.
LANCET NEUROLOGY, vol.16, no.12, pp.976-986, 2017 (SCI-Expanded)
- LXXVI. **Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS**
Lorscheider J., Jokubaitis V. G., Spelman T., Izquierdo G., Lugaresi A., Havrdova E., Horakova D., Trojano M., Duquette P., Girard M., et al.
NEUROLOGY, vol.89, no.10, pp.1050-1059, 2017 (SCI-Expanded)
- LXXVII. **Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice**
Spelman T., Meyniel C., Ignacio Rojas J., Lugaresi A., Izquierdo G., Grand'Maison F., BOZ C., Alroughani R., Havrdova E., Horakova D., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.23, no.10, pp.1346-1357, 2017 (SCI-Expanded)
- LXXVIII. **Towards personalized therapy for multiple sclerosis: prediction of individual treatment response**
Kalincik T., Manouchehrinia A., Sobisek L., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., Izquierdo G., Lugaresi A., et al.
BRAIN, vol.140, pp.2426-2443, 2017 (SCI-Expanded)
- LXXIX. **Prognostic Indicators in Pediatric Clinically Isolated Syndrome**
Iaffaldano P., Simone M., Lucisano G., Ghezzi A., Coniglio G., Morra V. B., Salemi G., Patti F., Lugaresi A., Izquierdo G., et al.
ANNALS OF NEUROLOGY, vol.81, no.5, pp.729-739, 2017 (SCI-Expanded)
- LXXX. **Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study**
Kalincik T., Brown J. W. L., Robertson N., Willis M., Scolding N., Rice C. M., Wilkins A., Pearson O., Ziemssen T., Hutchinson M., et al.
LANCET NEUROLOGY, vol.16, no.4, pp.271-281, 2017 (SCI-Expanded)
- LXXXI. **Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis**
Lizak N., Lugaresi A., Alroughani R., Lechner-Scott J., Slee M., Havrdova E., Horakova D., Trojano M., Izquierdo G., Duquette P., et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol.88, no.3, pp.196-203, 2017 (SCI-Expanded)
- LXXXII. **Contribution of different relapse phenotypes to disability in multiple sclerosis**
Stewart T., Spelman T., Havrdova E., Horakova D., Trojano M., Izquierdo G., Duquette P., Girard M., Prat A., Lugaresi A., et al.
MULTIPLE SCLEROSIS JOURNAL, vol.23, no.2, pp.266-276, 2017 (SCI-Expanded)
- LXXXIII. **Defining secondary progressive multiple sclerosis**
Lorscheider J., Buzzard K., Jokubaitis V., Spelman T., Havrdova E., Horakova D., Trojano M., Izquierdo G., Girard M., Duquette P., et al.
BRAIN, vol.139, pp.2395-2405, 2016 (SCI-Expanded)
- LXXXIV. **Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis**
Jokubaitis V. G., Spelman T., Kalincik T., Lorscheider J., Havrdova E., Horakova D., Duquette P., Girard M., Prat A., Izquierdo G., et al.
ANNALS OF NEUROLOGY, vol.80, no.1, pp.89-100, 2016 (SCI-Expanded)
- LXXXV. **The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis**

Warrender-Sparkes M, Spelman T, Izquierdo G, Trojano M, Lugaresi A, Grand'Maison F, Havrdova E, Horakova D, BOZ C, Oreja-Guevara C, et al.

MULTIPLE SCLEROSIS JOURNAL, vol.22, no.4, pp.520-532, 2016 (SCI-Expanded)

LXXXVI. Defining reliable disability outcomes in multiple sclerosis

Kalincik T, CUTTER G, Spelman T, Jokubaitis V, HAVRDOVA E, HORAKOVA D, TROJANO M, IZQUIERDO G, GIRARD M, DUQUETTE P, et al.

BRAIN, vol.138, 2015 (SCI-Expanded)

LXXXVII. Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort Demographic, Clinical, and Laboratory Features

Altintas A, KARABUDAK R, Balci B. P., TERZİ M., Soysal A., Saip S., Kurne A. T., Uygunoglu U., Nalbantoglu M., Celik G., et al.

NEUROLOGIST, vol.20, no.4, pp.61-66, 2015 (SCI-Expanded)

LXXXVIII. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Kalincik T, Jokubaitis V, IZQUIERDO G, DUQUETTE P, GIRARD M, Grammond P, LUGARESI A, OREJA-GUEVARA C, BERGAMASCHI R, HUPPERTS R, et al.

MULTIPLE SCLEROSIS JOURNAL, vol.21, no.9, pp.1159-1171, 2015 (SCI-Expanded)

LXXXIX. Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

Ribbons K. A., McElduff P., BOZ C., Trojano M., Izquierdo G., Duquette P., Girard M., Grand'Maison F., Hupperts R., Grammond P., et al.

PLOS ONE, vol.10, no.6, 2015 (SCI-Expanded)

XC. BREMSO: a simple score to predict early the natural course of multiple sclerosis

BERGAMASCHI R, MONTOMOLI C, MALLUCCI G, LUGARESI A, IZQUIERDO G, GRAND'MAISON F, DUQUETTE P, SHAYGANNEJAD V, ALROUGHANI R, GRAMMOND P, et al.

EUROPEAN JOURNAL OF NEUROLOGY, vol.22, no.6, pp.981-989, 2015 (SCI-Expanded)

XCII. Patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder: Turkish Multicenter Data

Altintas A, Karabudak R, Balci B. P., Terzi M., Soysal A., SAİP S., Kurne A. T., UYGUNOĞLU U., Nalbantoglu M., Gozubatik-Celik G., et al.

MULTIPLE SCLEROSIS JOURNAL, vol.21, no.6, pp.824-825, 2015 (SCI-Expanded)

XCIII. Predictors of disability worsening in clinically isolated syndrome

Jokubaitis V. G., Spelman T., Kalincik T., Izquierdo G., Grand'Maison F., Duquette P., Girard M., Lugaresi A., Grammond P., Hupperts R., et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, vol.2, no.5, pp.479-491, 2015 (SCI-Expanded)

XCIV. Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, et al.

ANNALS OF NEUROLOGY, vol.77, no.3, pp.425-435, 2015 (SCI-Expanded)

XCV. Seasonal Variation of Relapse Rate in Multiple Sclerosis is Latitude Dependent

Spelman T, Gray O, Trojano M, Petersen T, Izquierdo G, Lugaresi A, Hupperts R, Bergamaschi R, Duquette P, Grammond P, et al.

ANNALS OF NEUROLOGY, vol.76, no.6, pp.880-890, 2014 (SCI-Expanded)

XCVI. Evaluation of Temperament and Character Features as Risk Factors for Depressive Symptoms in Patients with Restless Legs Syndrome

Cakmak V., GAZİOĞLU S., USTA N. C., Ozkorumak E., AYAR A., TOPBAŞ M., BOZ C.

JOURNAL OF CLINICAL NEUROLOGY, vol.10, no.4, pp.320-327, 2014 (SCI-Expanded)

XCVII. Factors associated with early hospital arrival in acute ischemic stroke patients

KOKSAL E. K., GAZİOĞLU S., BOZ C., ÇAN G., ALİOĞLU Z.

NEUROLOGICAL SCIENCES, vol.35, no.10, pp.1567-1572, 2014 (SCI-Expanded)

XCVIII. Risk of relapse phenotype recurrence in multiple sclerosis

- KALINCIK T., BUZZARD K., Jokubaitis V., TROJANO M., DUQUETTE P., IZQUIERDO G., GIRARD M., LUGARESI A., Grammond P., GRAND'MAISON F., et al.
 MULTIPLE SCLEROSIS JOURNAL, vol.20, no.11, pp.1511-1522, 2014 (SCI-Expanded)
- XCVIII. **Predictors and dynamics of postpartum relapses in women with multiple sclerosis**
 HUGHES S. E., SPELMAN T., GRAY O. M., BOZ C., TROJANO M., LUGARESI A., IZQUIERDO G., DUQUETTE P., GIRARD M., GRAND'MAISON F., et al.
 MULTIPLE SCLEROSIS JOURNAL, vol.20, no.6, pp.739-746, 2014 (SCI-Expanded)
- XCIX. **Personality Traits of Patients With Multiple Sclerosis and Their Relationship With Clinical Characteristics**
 GAZIÖĞLU S., Cakmak V. A., Ozkorumak E., USTA N. C., Ates C., BOZ C.
 JOURNAL OF NERVOUS AND MENTAL DISEASE, vol.202, no.5, pp.408-411, 2014 (SCI-Expanded)
- C. **Fingolimod after natalizumab and the risk of short-term relapse**
 Jokubaitis V. G., Li V., Kalincik T., Izquierdo G., Hodgkinson S., Alroughani R., Lechner-Scott J., Lugaresi A., Duquette P., Girard M., et al.
 NEUROLOGY, vol.82, no.14, pp.1204-1211, 2014 (SCI-Expanded)
- CI. **Sex as a determinant of relapse incidence and progressive course of multiple sclerosis**
 Kalincik T., VIVEK V., Jokubaitis V., LECHNER-SCOTT J., TROJANO M., IZQUIERDO G., LUGARESI A., GRAND'MAISON F., HUPPERTS R., OREJA-GUEVARA C., et al.
 BRAIN, vol.136, pp.3609-3617, 2013 (SCI-Expanded)
- CII. **Fluctuations of MS births and UV-light exposure**
 VERHEUL F., SMOLDERS J., TROJANO M., LEPORE V., ZWANIKKEN C., AMATO M. P., GRAND'MAISON F., Butzkueven H., MARROSU M., DUQUETTE P., et al.
 ACTA NEUROLOGICA SCANDINAVICA, vol.127, no.5, pp.301-308, 2013 (SCI-Expanded)
- CIII. **Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study**
 Iuliano G., BOZ C., Cristiano E., Duquette P., Lugaresi A., Oreja-Guevara C., Van Pesch V.
 JOURNAL OF NEUROLOGY, vol.260, no.5, pp.1258-1262, 2013 (SCI-Expanded)
- CIV. **Clinical Characteristics and Prognosis of Guillain Barre Syndrome**
 GAZIÖĞLU S., TOMAK T., BOZ C.
 JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, vol.30, no.1, pp.124-134, 2013 (SCI-Expanded)
- CV. **Cerebral venous thrombosis after high dose steroid in multiple sclerosis: a case report**
 GAZIÖĞLU S., SOLMAZ D., BOZ C.
 HIPPOKRATIA, vol.17, no.1, pp.88-90, 2013 (SCI-Expanded)
- CVI. **Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis**
 Trojano M., Lucchese G., Graziano G., Taylor B. V., Simpson S., Lepore V., Grand'Maison F., Duquette P., Izquierdo G., Grammond P., et al.
 PLOS ONE, vol.7, no.10, 2012 (SCI-Expanded)
- CVII. **Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study**
 ALTINTAŞ A. T., PETEK B., ISIK N., Terzi M., BOLUKBASI F., TAVSANLI M., SAIP S., BOZ C., AYDIN T., ARICI-DUZ O., et al.
 MULTIPLE SCLEROSIS JOURNAL, vol.18, no.10, pp.1448-1453, 2012 (SCI-Expanded)
- CVIII. **Ocular and cervical vestibular evoked myogenic potentials in multiple sclerosis patients**
 GAZIÖĞLU S., BOZ C.
 CLINICAL NEUROPHYSIOLOGY, vol.123, no.9, pp.1872-1879, 2012 (SCI-Expanded)
- CIX. **Magnetic resonance imaging in bilateral brachial neuritis with pure sensory involvement**
 GAZIÖĞLU S., BOZ C., SARI A.
 NEUROLOGICAL SCIENCES, vol.33, no.4, pp.927-930, 2012 (SCI-Expanded)
- CX. **Increasing age at disability milestones among MS patients in the MSBase Registry**
 Kister I., CHAMOT E., CUTTER G., Bacon T. E., JOKUBAITIS V. G., HUGHES S. E., GRAY O. M., TROJANO M., IZQUIERDO G., GRAND'MAISON F., et al.
 JOURNAL OF THE NEUROLOGICAL SCIENCES, vol.318, pp.94-99, 2012 (SCI-Expanded)

- CXI. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude**
 LECHNER-SCOTT J, SPENCER B, DE MALMANCHE T, Attia J, Fitzgerald M, TROJANO M, GRAND'MAISON F, GOMEZ J. A. C., IZQUIERDO G., DUQUETTE P., et al.
 MULTIPLE SCLEROSIS JOURNAL, vol.18, no.7, pp.974-982, 2012 (SCI-Expanded)
- CXII. Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome**
 MEYNIEL C., SPELMAN T., JOKUBAITIS V. G., TROJANO M., IZQUIERDO G., GRAND'MAISON F., OREJA-GUEVARA C., BOZ C., LUGARESI A., Girard M., et al.
 PLOS ONE, vol.7, no.6, 2012 (SCI-Expanded)
- CXIII. Cervical vestibular evoked myogenic potentials to air-conducted sound in early amyotrophic lateral sclerosis**
 KILIC S., GAZIÖĞLU S., ZENGIN K. S., DUBUS H. U., BOZ C.
 NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY, vol.42, no.3, pp.119-123, 2012 (SCI-Expanded)
- CXIV. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry**
 Hughes S., Spelman T., Trojano M., Lugaresi A., Izquierdo G., Grand'Maison F., Duquette P., Girard M., Grammond P., Oreja-Guevara C., et al.
 JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol.83, no.3, pp.305-310, 2012 (SCI-Expanded)
- CXV. Basilar artery occlusion in migraine-like headache: a possible triggering effect of sumatriptan**
 GAZIÖĞLU S., BOZ C., Ozmenoglu M.
 NEUROLOGICAL SCIENCES, vol.33, no.1, pp.125-128, 2012 (SCI-Expanded)
- CXVI. The effect of pregnancy on relapse rate and disability progression in MS: results from the MSBase Registry**
 Hughes S. E., Spelman T., Gray O. M., Boz C., Trojano M., Zwanikken C., Lugaresi A., Izquierdo G., Duquette P., Girard M., et al.
 MULTIPLE SCLEROSIS JOURNAL, vol.17, 2011 (SCI-Expanded)
- CXVII. Ultra-annual changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicentre study**
 Iuliano G., Boz C., Cristiano E., Duquette P., Lugaresi A., Van Pesch V.
 MULTIPLE SCLEROSIS JOURNAL, vol.17, 2011 (SCI-Expanded)
- CXVIII. Electrodiagnosis of carpal tunnel syndrome in patients with diabetic polyneuropathy**
 GAZIÖĞLU S., BOZ C., ÇAKMAK V. A.
 CLINICAL NEUROPHYSIOLOGY, vol.122, no.7, pp.1463-1469, 2011 (SCI-Expanded)
- CXIX. VEMP responses are not affected in non-insulin-dependent diabetes mellitus patients with or without polyneuropathy**
 BEKTAS D., GAZIÖĞLU S., ARSLAN S., COBANOĞLU B., BOZ C., CAYLAN R.
 ACTA OTO-LARYNGOLOGICA, vol.128, no.7, pp.768-771, 2008 (SCI-Expanded)
- CXX. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study**
 Boz C., OGER J., GIBBS E., GROSSBERG S. E.
 MULTIPLE SCLEROSIS, vol.13, no.9, pp.1127-1137, 2007 (SCI-Expanded)
- CXXI. Effect of serotonergic antidepressant therapy on temperament and character scales in patients with chronic tension-type headache**
 Boz C., Gazioglu S., ALTUNAYOĞLU V., HOCAOĞLU C.
 PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.61, no.5, pp.534-542, 2007 (SCI-Expanded)
- CXXII. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in multiple sclerosis**
 Boz C.
 CLINICAL NEUROLOGY AND NEUROSURGERY, vol.108, no.6, pp.618, 2006 (SCI-Expanded)
- CXXIII. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy**
 Kister I., Gulati S., Boz C., Bergamaschi R., Piccolo G., Oger J., Swerdlow M.
 ARCHIVES OF NEUROLOGY, vol.63, no.6, pp.851-856, 2006 (SCI-Expanded)

- CXXIV. **Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta**
Boz C., Ozmenoglu M., Velioglu S., Kilinc K., Orem A., Alioglu Z., Altunayoglu V.
Clinical Neurology and Neurosurgery, vol.108, no.2, pp.124-128, 2006 (SCI-Expanded)
- CXXV. **The impact of migraine on epilepsy: a prospective prognosis study**
Velioglu S., Boz C., Ozmenoglu M.
CEPHALALGIA, vol.25, no.7, pp.528-535, 2005 (SCI-Expanded)
- CXXVI. **Temperament and character profiles of patients with tension-type headache and migraine**
Boz C., Velioglu S., Ozmenoglu M., Sayar K., Alioglu Z., Yalman B., Topbas M.
PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.58, no.5, pp.536-543, 2004 (SCI-Expanded)
- CXXVII. **Individual risk factors for carpal tunnel syndrome: an evaluation of body mass index, wrist index and hand anthropometric measurements**
Boz C., Ozmenoglu M., Altunayoglu V., Velioglu S., Alioglu Z.
CLINICAL NEUROLOGY AND NEUROSURGERY, vol.106, no.4, pp.294-299, 2004 (SCI-Expanded)
- CXXVIII. **The efficacy and safety of dipyron (Novalgin (R)) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study**
Tulunay F., Ergun H., Gulmez S., Ozbenli T., Ozmenoglu M., Boz C., Erdemoglu A., Varlikbas A., Goksan B., Inan L.
FUNCTIONAL NEUROLOGY, vol.19, no.3, pp.197-202, 2004 (SCI-Expanded)
- CXXIX. **The efficacy and safety of dipyron (Novalgin®) tablets in the treatment of acute migraine attacks: A double-blind, cross-over, randomized, placebo-controlled, multi-center study**
Tulunay F. C., ERGÜN H., Gülmez S. E., Özbenli T., Özmenoğlu M., Boz C., Erdemoglu A. K., Varlikbas A., Göksan B., Inan L.
Functional Neurology, vol.19, no.3, pp.197-202, 2004 (SCI-Expanded)
- CXXX. **Transient Tic disorder following carbon monoxide poisoning**
Alioglu Z., BOZ C., SARI A., AYNACI M.
JOURNAL OF NEURORADIOLOGY, vol.31, no.3, pp.231-233, 2004 (SCI-Expanded)
- CXXXI. **Guillain-Barre syndrome during treatment with interferon alpha for hepatitis B**
BOZ C., OZMENOGU M., AKTOZ G., VELIOGLU S., Alioglu Z.
JOURNAL OF CLINICAL NEUROSCIENCE, vol.11, no.5, pp.523-525, 2004 (SCI-Expanded)
- CXXXII. **Kronik gerilim tipi baş ağrılı hastalarda mizaç ve karakter profili**
BOZ C., Sayar K., VELIOGLU S., Hocaoğlu Ç., ALİOĞLU Z., YALMAN B., OZMENOGU M.
Türk Psikiyatri Derg., vol.15, no.2, pp.105-111, 2004 (SCI-Expanded)
- CXXXIII. **Benign acute childhood myositis**
SONMEZ F., CAKIR M., YAYLA S., Boz C.
MEDICAL PRINCIPLES AND PRACTICE, vol.13, no.4, pp.227-229, 2004 (SCI-Expanded)
- CXXXIV. **Isolated hypoglossal nerve palsy in a child**
AYNACI F., SEN Y., Boz C., ORHAN F.
TURKISH JOURNAL OF PEDIATRICS, vol.46, no.1, pp.101-103, 2004 (SCI-Expanded)
- CXXXV. **Temperament and character profile of patients with chronic tension-type headache Kronik Gerilim Tipi Baş Ağrılı Hastalarda Mizaç ve Karakter Profili.**
BOZ C., Sayar K., VELİOĞLU S., HOCAOĞLU Ç., ALİOĞLU Z., Yalman B., Ozmenoglu M.
Türk psikiyatri dergisi = Turkish journal of psychiatry, vol.15, no.2, pp.105-111, 2004 (SCI-Expanded)
- CXXXVI. **Sertraline versus amitriptyline in the prophylactic therapy of non-depressed chronic tension-type headache patients**
BOZ C., Altunayoglu V., VELİOĞLU S., Ozmenoglu M.
Journal of Headache and Pain, vol.4, no.2, pp.72-78, 2003 (SCI-Expanded)
- CXXXVII. **Central nervous system involvement in autoimmune polyglandular syndrome**
Boz C., Velioglu S., Altunayoglu V., Ozmenoglu M., Erem C.
CLINICAL NEUROLOGY AND NEUROSURGERY, vol.105, no.2, pp.102-104, 2003 (SCI-Expanded)
- CXXXVIII. **Acute disseminated encephalomyelitis after bee sting**
Boz C., Velioglu S., Omenoglu M.

- NEUROLOGICAL SCIENCES, vol.23, no.6, pp.313-315, 2003 (SCI-Expanded)
- CXXXIX. **X-linked spinal and bulbar muscular atrophy without proximal atrophy**
Boz C., Sahin N., Kalay E., Velioglu S., Ozmenoglu M.
CLINICAL NEUROLOGY AND NEUROSURGERY, vol.105, no.1, pp.14-17, 2002 (SCI-Expanded)
- CXL. **Relationship between major depression and heart rate variability. Clinical consequences and implications for antidepressive treatment**
Agelink M., Boz C., Ullrich H., Andrich J.
PSYCHIATRY RESEARCH, vol.113, no.1-2, pp.139-149, 2002 (SCI-Expanded)
- CXLI. **Fatal brainstem infarction after apheresis donation**
BOZ C., VELIOGLU S., Altunayoğlu Çakmak V., ALIOĞLU Z., OZMENOGLU M.
e-Journal of Neurological Sciences - Turkish, vol.19, no.3, pp.35-50, 2002 (SCI-Expanded)
- CXLII. **Evaluation of plasma endothelin-1 levels in patients with cerebral infarction**
Alioglu Z., OREM A., BULBUL I., BOZ C., OZMENOGLU M., VANIZOR B.
ANGIOLOGY, vol.53, no.1, pp.77-82, 2002 (SCI-Expanded)
- CXLIII. **Baclofen is effective in intractable hiccups induced by brainstem lesions**
Boz C., Velioglu S., Bulbul I., Ozmenoglu M.
NEUROLOGICAL SCIENCES, vol.22, no.5, pp.409, 2001 (SCI-Expanded)
- CXLIV. **Status epilepticus after stroke**
VELIOGLU S., OZMENOGLU M., BOZ C., Alioglu Z.
STROKE, vol.32, no.5, pp.1169-1172, 2001 (SCI-Expanded)
- CXLV. **Cerebral infarction following intravenous immunoglobulin therapy for Guillain-Barre syndrome**
VELIOĞLU S., Özmenoğlu M., BOZ C.
Journal of Stroke and Cerebrovascular Diseases, vol.10, no.6, pp.290-292, 2001 (SCI-Expanded)
- CXLVI. **Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage**
ALIOĞLU Z., BULBUL I., OREM A., OZMENOGLU M., VANIZOR B., BOZ C.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, vol.9, pp.176-180, 2000 (SCI-Expanded)
- CXLVII. **Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage**
ALIOĞLU Z., Bülbül I., ÖREM A., Özmenoğlu M., KURAL B., BOZ C.
Journal of Stroke and Cerebrovascular Diseases, vol.9, no.4, pp.176-180, 2000 (SCI-Expanded)

Articles Published in Other Journals

- I. **A Case Report of Acute Disseminated Encephalomyelitis in a Pregnant Woman After COVID-19 Infection**
KIZILIRMAK R., ÖZALP M., OSMANAĞAOĞLU M. A., BOZ C.
TURK NOROLOJI DERGISI, vol.27, pp.49-51, 2021 (ESCI)
- II. **Genotype phenotype correlation of cadasil patients-single center experience**
ÇEBİ A. H., BOZ C.
Annals of Medical Research, vol.28, no.02, pp.381-384, 2021 (Peer-Reviewed Journal)
- III. **Nöro-Behçet Hastalığında Klinik Özellikler**
Gazioglu S., Boz M., Aksu Arıca D., Boz C.
Dicle Tıp Dergisi, vol.47, no.2, pp.324-330, 2020 (Peer-Reviewed Journal)
- IV. **The COVID-19 from Neurological Overview**
ACAR T., ACIMAN DEMİREL E., AFŞAR FAK N. E. Y., AKÇALI A., AKMAN DEMİR G., ALAGÖZ A. N., ANGIN MENGİ T., ARSAVA E. M., AYTA S., BEBEK N., et al.
Turkish Journal Of Neurology, vol.26, no.2, pp.58-108, 2020 (ESCI)
- V. **The Efficacy of Acupuncture in the Treatment of Bell's Palsy Sequelae**
ERTEMOĞLU ÖKSÜZ C., Kalaycioglu A., UZUN Ö., KALKIŞIM Ş. N., ZİHNİ N. B., Yildirim A., BOZ C.
JOURNAL OF ACUPUNCTURE AND MERIDIAN STUDIES, vol.12, no.4, pp.122-130, 2019 (ESCI)
- VI. **The efficacy of acupuncture in the treatment of Bell's palsy sequelae**

ERTEMOĞLU ÖKSÜZ C., KALAYCIOĞLU A., UZUN Ö., KALKIŞIM Ş. N., ZİHNİ N. B., Yıldırım A., BOZ C.
JOURNAL OF ACUPUNCTURE AND MERIDIAN STUDIES, 2019 (Scopus)

- VII. **Clinical and morphometric examination of acupuncture effect in Bell's palsy sequelae**
Oksuz C., Kalaycioglu A., Yildirim A., Uzun Ö., Kalkışım Ş. N., Zihni N. B., Boz C.
CUKUROVA MEDICAL JOURNAL, vol.44, pp.11-19, 2019 (ESCI)
- VIII. **Pediatric Yaş Başlangıçlı Multipl Skleroz ile Erişkin Yaş Başlangıçlı Multipl Sklerozun Karşılaştırılması**
DİLBER B., DİLER DURGUT B., ACAR ARSLAN E., ŞAHİN S., CANSU A., BOZ C., TERZİ M.
TURKİYE KLİNİKLERİ JOURNAL OF NEUROLOGY, 2019 (Peer-Reviewed Journal)
- IX. **A rare metabolic disease: cerebrotendinous xanthomatosis**
Kamaşak T., Demirhan Y. N., Pariltan Küçükalioglu B., Boz C., Çebi A. H., Eyüboğlu İ., Cansu A.
Van Medical Journal, vol.26, no.2, pp.265-267, 2019 (Peer-Reviewed Journal)
- X. **Pregnancy-induced Susac Syndrome: A Case Report**
Usta N. C., BOZ C., Ozmenoglu M.
TURKISH JOURNAL OF NEUROLOGY, vol.24, no.1, pp.70-71, 2018 (ESCI)
- XI. **A Comparison of Pediatric- and Adult-Onset Multiple Sclerosis**
KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DİLER DURGUT B., DİLBER B., KURT T., TERZİ M., BOZ C.
Turkiye Klinikleri Journal of Neurology, vol.12, no.3, pp.57-63, 2017 (Peer-Reviewed Journal)
- XII. **Pediatric Yaş Başlangıçlı Multipl Skleroz ile Erişkin Yaş Başlangıçlı Multipl Sklerozun Karşılaştırılması A Comparison of Pediatric- and Adult-Onset Multiple Sclerosis**
KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DİLER DURGUT B., DİLBER B., KURT T., TERZİ M., BOZ C.
Turkiye Klinikleri Journal of Neurology, vol.12, no.3, pp.57-63, 2017 (Peer-Reviewed Journal)
- XIII. **Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS**
Spelman T., Kalincik T., Jokubaitis V., Zhang A., Pellegrini F., Wiendl H., Belachew S., Hyde R., Verheul F., Lugaresi A., et al.
NEUROLOGY-CLINICAL PRACTICE, vol.6, no.2, pp.102-115, 2016 (ESCI)
- XIV. **Demiyelizan Hastalıklar ve Önlenebilir Acil Durumlar**
ALTIPARMAK D., BOZ C.
türkiye klinikleri, 2016 (Peer-Reviewed Journal)
- XV. **Lack of Association between Pulse Steroid Therapy and Bone Mineral Density in Patients with Multiple Sclerosis**
Karahan S. Z., BOZ C., Kilic S., Usta N. C., Ozmenoglu M., ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S.
MULTIPLE SCLEROSIS INTERNATIONAL, vol.2016, 2016 (ESCI)
- XVI. **Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry**
Rojas J. I., Patrucco L., Trojano M., Lugaresi A., Izquierdo G., Butzkueven H., Jokubaitis V., Duquette P., Girard M., Grand'Maison F., et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical, vol.1, 2015 (Scopus)
- XVII. **Anomalik İnnervasyonlar**
GAZİOĞLU S., BOZ C.
ürkiye Klinikleri Nöroloji Özel Dergisi- Elektromiyografi (EMG) Özel Sayısı, no.6, pp.24-30, 2014 (Peer-Reviewed Journal)
- XVIII. **Ocular myasthenia gravis associated with X-linked recessive spinal and bulbar muscular atrophy**
Boz C., Kalay E., Sahin N., VELİOĞLU S., Ozmenoglu M., Karagüzel A.
Journal of Clinical Neuromuscular Disease, vol.5, no.3, pp.115-118, 2004 (Scopus)
- XIX. **Local cold effect on the excitability recovery curve of the sympathetic skin response**
BOZ C., ÖZMENOĞLU M., ALİOĞLU Z., VELİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S.
electromyography and clinical neurophysiology, 2004 (Peer-Reviewed Journal)
- XX. **Tissue plasminogen activator mass concentration in ischemic acute stroke patients**
BOZ C., AKBAS A., ALİOĞLU Z., OZMENOGU M.
Turkish Journal of Medical Sciences, vol.33, no.3, pp.155-159, 2003 (Scopus)

- XXI. **Gebelik ve loğusalıkta akut strok olayları**
ALİOĞLU Z., ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZMENOĞLU M.
Türk Serebrovasküler Hastalıklar Dergisi, vol.9, no.2, pp.63-66, 2003 (Peer-Reviewed Journal)
- XXII. **Plasma homocysteine in acute and subacute phases after ischemic stroke İskemik strok'ta akut ve subakut dönem homosistei n düzeyleri**
VELİOĞLU S., BOZ C., Ari N., Uydu H. A., Özmenoğlu M.
Turk Beyin Damar Hastalıklar Dergisi, vol.9, no.1, pp.1-5, 2003 (Scopus)
- XXIII. **Epilepsili hastalarda kognitif fonksiyonların olaya ilişkin endojen potansiyellerle (P300) değerlendirilmesi**
BOZ C., VELİOĞLU S., ALİOĞLU Z., OZMENOGLU M.
TÜRK NÖROLOJİ DERGİSİ, vol.1, pp.53-61, 2003 (ESCI)
- XXIV. **Diyabetik Nöropati**
GAZİOĞLU S., BOZ C.
Galenos Tıp Dergisi, pp.24-35, 2003 (Peer-Reviewed Journal)
- XXV. **Treatment of intractable hiccups Dirençli hiçkirkirklarda tedavi**
BOZ C., VELİOĞLU S., Özmenoğlu M.
SENDROM, vol.14, no.12, pp.70-73, 2002 (Scopus)
- XXVI. **Fatal brainstem infarction after apheresis donation.**
BOZ C., VELİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., ALİOĞLU Z., ÖZMENOĞLU M.
JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, vol.19, no.3, pp.1-9, 2002 (Peer-Reviewed Journal)
- XXVII. **Non-ketojenik hiperglisemiye bağlı hemibalismus-hemikore ve kraniyal magnetik rezonans görüntüleme**
ALİOĞLU Z., BOZ C., OZMENOGLU M.
Parkinson Hastalığı ve Hareket Bozuklukları Dergisi, vol.5, no.2, pp.62-66, 2002 (Non Peer-Reviewed Journal)
- XXVIII. **Eklamptik ve preeklamptik olgularda elektroensefalografi ve kraniyal magnetik rezonans görüntüleme bulguları**
ALİOĞLU Z., VELİOĞLU S., Dinç G., BOZ C., DINC H., OZMENOGLU M.
EPILEPSY, vol.1, pp.21-25, 2002 (Scopus)
- XXIX. **The Effects of Pentoxifylline in Experimental Nerve Injury**
BAYKAL S., BOZ C., ÇAKIR E., BAYTAN Ş. H., KARAKUŞ M., KUZEYLİ K.
TURKISH JOURNAL OF MEDICAL SCIENCES, no.32, pp.207-210, 2002 (Scopus)
- XXX. **Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage**
ALIOGLU Z., Bülbül İ., ÖREM A., OZMENOGLU M., KURAL B., BOZ C.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, vol.9, no.4, pp.176-180, 2000 (Scopus)
- XXXI. **Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage**
ALIOGLU Z., Bülbül İ., ÖREM A., OZMENOGLU M., KURAL B., BOZ C.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, vol.9, no.4, pp.176-180, 2000 (Scopus)
- XXXII. **Serebrovasküler hastalık sonrası gelişen epilepsi nöbetleri.**
VELİOĞLU S., BOZ C., ALİOĞLU Z., OZMENOGLU M., Yalman B.
TÜRK NÖROLOJİ DERGİSİ, vol.6, no.4, pp.39-45, 2000 (ESCI)

Books & Book Chapters

- I. **Myastenia Gravis**
BOZ C.
Sakarya, 2020
- II. **Multipl Skleroz**
BOZ C., TERZİ M., BÖLÜKBAŞI O.
Sakarya, 2020
- III. **Multipl Skleroz Tedavi Geçişlerinde Uygulamalar**

AKÇALI A., AKSOY D., Altıntaş A., ALTUN Y., ALTUNRENDE B., ARDUÇ AKÇAY A., BİLGE N., BİR L. S., BOZ C., Bünül D., et al.
in: Türkiye Klinikleri Nöroloji Özel Konular-Multipl Skleroz, Duman Taşkın, Editor, Türkiye Klinikleri, pp.88-93, 2020

- IV. **Soru ve Yanıtlarla Multipl Skleroz**
TERZİ M., BOZ C., BÖLÜKBAŞI O.
No-bel Matbaacılık San.Tic.Ltd. Şti., 2018
- V. **Soru ve Yanıtlar ile Multipl Skleroz**
BOZ C., TERZİ M., BÖLÜKBAŞI O.
Ömür matbaacılık, 2016
- VI. **Soru ve Yanıtlar ile Myastenia Gravis**
BOZ C.
Sakarya, 2015
- VII. **Benim MS im öyküler**
BOZ C., TERZİ M., Turan Ö.
Sakarya, 2014

Refereed Congress / Symposium Publications in Proceedings

- I. **The Effect of Pregnancy on Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Associated Disease Activity and Progression: A Multi-center Retrospective Study from Turkey**
Uzunkopru C., Şen S., Altıntaş A., ÇAKAN ERCAN M., BÜNÜL S. D., Demir G. A., Balci F. B., Gursoy E. A., Arslan G., KOÇ E. R., et al.
9th JointECTRIMS-ATRIMS meeting, Milan, Italy, 11 - 13 October 2023, pp.664
- II. **AN UNUSUAL REASON OF BACK PAIN AND WEAKNESS: SPINAL CORD INFARCTION**
CANDAŞ K. B., KURŞUN S., GÜL K., YÜKSEL Z. Ö., İMAMOĞLU M., ÖZER V., PASLI S., KARACA Y., BOZ C.
17th WINFOCUS WORLD CONGRESS & 8th EURASIAN CONGRESS ON EMERGENCY MEDICINE, Turkey, 1 - 04 December 2022
- III. **Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study**
Butzkueven H., Spelman T., ÖZAKBAŞ S., Laureys G., Van Hijfte L., Alroughani R., Menoyo J. L. S., Van Pesch V., Kalincik T., Lechner-Scott J., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.384-386
- IV. **Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS**
Kalincik T., Sharman S., Roos I., Freedman M., Atkins H., Burman J., Massey J., Sutton I., Withers B., Macdonell R., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.11-14
- V. **The risk of secondary progressive multiple sclerosis is geographically determined but modifiable**
Sharmin S., Roos I., Simpson-Yap S., Malpas C., Sanchez M. M., ÖZAKBAŞ S., Horakova D., Havrdova E. K., Patti F., Alroughani R., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.967-970
- VI. **A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis**
Roos I., Hughes S., MacDonnell G., Boz C., Alroughani R., Ozakbas S., Buzzard K., Skibina O., Van der Walt A., Butzkueven H., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.951-953

- VII. **Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation**
Zhu C., Kalincik T., Horakova D., Zhen Z., Buzzard K., Skibina O., Alroughani R., Izquierdo G., Eichau S., Kuhle J., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.645-647
- VIII. **Medulla oblongata volume measured from clinical routine T2-FLAIR scans is associated with disability progression in a multiple sclerosis real-world dataset**
Bergsland N., Barnett M., Weinstock-Guttman B., Butzkueven H., Kalincik T., Desmond P., Gaillard F., van Pesch V., ÖZAKBAŞ S., Rojas J. I., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.289-290
- IX. **Emulating randomized clinical trials in relapsing-remitting multiple sclerosis with nonrandomized real-world evidence: an application using data from the MSBase registry**
Ponzano M., ÖZAKBAŞ S., Horakova D., Havrdova E., Terzi M., Alroughani R., Patti F., Kuhle J., Izquierdo G., Eichau S., et al.
38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.379-380
- X. **Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis**
Spelman T., Acosta C., Hyde R., Campbell N., Havrdova E., Horakova D., Trojano M., De Luca G., Lugaresi A., Izquierdo G., et al.
8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), ELECTR NETWORK, 11 - 13 September 2020, vol.26, pp.526-527
- XI. **Distal Tübüler Asidoz, Osteopetrozis ve Serebral Kalsifikasyonu Olan Bir Vaka,?**
KAYNAR R. K., BOZ C., ULUSOY Ş., ÖZMENOĞLU M., Gül S.
4. Ulusal Hipertansiyon ve Böbrek Hastalıkları Kongresi,, Antalya, Turkey, pp.56
- XII. **Distal Tübüler Asidoz, Osteopetrozis ve Serebral Kalsifikasyonu Olan Bir Vaka,?**
KAYNAR R. K., BOZ C., ULUSOY Ş., ÖZMENOĞLU M., Gül S.
4. Ulusal Hipertansiyon ve Böbrek Hastalıkları Kongresi,, Antalya, Turkey, pp.56
- XIII. **Determinants of Therapeutic Lag in Multiple Sclerosis (2059)**
Roos I., Leray E., Frascoli F., Horakova D., Trojano M., Patti F., ÖZAKBAŞ S., BOZ C., TERZİ M., TÜRKOĞLU R., et al.
American Academy of Neurology, United States Of America, 14 - 27 April 2020, vol.94, pp.2059
- XIV. **Identification of Therapeutic Lag in Multiple Sclerosis**
ROOS I., Leray E., FRASCOLI F., Casey R., Horakova D., Havrdova E., Trojano M., GI A., Madueno S., Patti F., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 25 February - 01 March 2020
- XV. **Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis**
Kalincik T., Ibrahima D., Malpas C., Horakova D., Havrdova E., Trojano M., Ayuso G., Eichau S., Onafri M., Lugaresi A., et al.
Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 25 April - 01 May 2020
- XVI. **Identification of Therapeutic Lag in Multiple Sclerosis (1787)**
Roos I., Leray E., Frascoli F., Horakova D., Trojana M., ÖZAKBAŞ S., BOZ C., TERZİ M., TÜRKOĞLU R., Butzkueven H., et al.
American Academy of Neurology, United States Of America, 14 - 19 April 2020, vol.94, pp.1787
- XVII. **Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis (2002)**
Sharmin S., Bovis F., Malpas C. B., Horakova D., Trojana M., BOZ C., ÖZAKBAŞ S., TERZİ M., TÜRKOĞLU R., Sormani M. P., et al.
American Academy of Neurology, United States Of America, 14 - 26 April 2020, vol.94, pp.2002
- XVIII. **of Therapeutic Lag in Relapsing Multiple Sclerosis**
ROOS I., FRASCOLI F., Horakova D., Havrdova E., Trojano M., Izquierdo G., Eichau S., Patti F., Prat A., Girard M., et al.
Conference of MS-Research-Australia, 31 October - 01 November 2019
- XIX. **SS-46 OCRELİZUMAB TEDAVİSİ GERÇEK YAŞAM VERİLERİ:3 MULTİPL SKLEROZ MERKEZİNİN TECRÜBELERİ**

VURAL E., TERZİ M., Sunter G., AĞAN YILDIRIM K., BOZ C.

55. Ulusal Nöroloji Kongresi, Turkey, 15 November 2018 - 21 November 2019

- XX. **BİR ULUSAL ÇALIŞMANIN YÖNTEMİ (ENVIROPIMS): YENİ TANI ALMIŞ ERİŞKİN, ERGEN VE ÇOCUK MULTİPLE SKLEROZ(MS) OLGULARINDA OBEZİTE, SAĞLIKLI BESLENME VE FİZİKSEL AKTİVİTE DURUMUNUN ARAŞTIRILMASI**
YÜCEYAR A. N., AKMAN DEMİR G., ALTUNRENDE B., BECKMANN Y., BOZ C., CANBAZ KABAY S., ÇİLİNGİR V., DEMİRKIRAN D. M., DEMİR C. F., EFENDİ H., et al.
55. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 15 - 21 November 2019
- XXI. **SS-78 GEÇ VE ERKEN BAŞLANGIÇLI MULTİPLE SKLEROZHASTALARINDA, KLİNİK VE HASTALIK PROGRESYONUFARKLILIKLARI**
ZENGİN KARAHAN S., bilgiç a. b., KARAMAN A. G., BOZ C., TERZİ M.
55. Ulusal Nöroloji Kongresi, Turkey, 15 - 21 November 2019
- XXII. **Multipl Skleroz Hastalarında Fingolimod Tedavisinin Etkililiği : Türkiye Gerçek Yaşam Verileri**
TUNCER M. A., UYGUNOĞLU U., TERZİ M., KÜRTÜNCÜ M., YÜCEYAR A. N., EKMEKÇİ Ö., TÜRKÖĞLU R., SOYSAL A., KÖSEOĞLU M., GÖZÜBATIK ÇELİK R. G., et al.
55. Ulusal Nöroloji Kongresi, Antalya, Turkey, 15 - 21 November 2019
- XXIII. **TEP-147 MULTİPL SKLEROZ HASTALARINDA FİNGOLİMODTEDAVİSİNİN ETKİLİLİĞİ : TÜRKİYE GERÇEK YAŞAMVERİLERİ (REFINE)**
TUNCER M. A., UYGUNOĞLU U., TERZİ M., KÜRTÜNCÜ M., YÜCEYAR A. N., Ekmekci Ö., Türkoğlu R., Soysal A., KÖSEOĞLU M., GÖZÜBATIK ÇELİK G., et al.
55. Ulusal Nöroloji Kongresi, Antalya, Turkey, 16 - 20 November 2019, pp.276
- XXIV. **SS-77 BİR ULUSAL ÇALIŞMANIN YÖNTEMİ (ENVIROPIMS):YENİ TANI ALMIŞ ERİŞKİN, ERGEN VE ÇOCUK MULTİPLESKLEROZ(MS) OLGULARINDA OBEZİTE, SAĞLIKLIBESLENME VE FİZİKSEL AKTİVİTE DURUMUNUNARAŞTIRILMASI**
YÜCEYAR A. N., AKMAN G., ALTUNRENDE B., BECKMANN Y., BOZ C., CANBAZ KABAY S., ÇİLİNGİR V., DEMİRKIRAN D. M., DEMİR C. F., EFENDİ H., et al.
55. Ulusal Nöroloji Kongresi, Antalya, Turkey, 16 - 20 November 2019, pp.45
- XXV. **Self-management and coping strategies in patients with multipl sclerosis multicenter -prospective study**
BOZ C., ÜNAL A., AKÇALI A., ALTUNRENDE B.
ECTRIMS, 11 - 13 September 2019
- XXVI. **Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS**
Kalincik T., Malpas C. B., Sharmin S., Roos I., Patti F., Butzkueven H., Alroughani R., Izquierdo G., Eichau S., Onofrj M., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.912-914
- XXVII. **Modifiers of the effectiveness of MS immunotherapies**
Kalincik T., Malpas C., Sharmin S., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., Eichau S., Onofrj M., Lugaresi A., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.791-793
- XXVIII. **Therapeutic lag in relapsing multiple sclerosis**
Roos I., Frascoli F., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., Eichau S., Patti F., Onofr M., Lugaresi A., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.564-565
- XXIX. **Personalizing treatment effect based on patient's baseline profile: a statistical modelling approach applied to randomized clinical trial and observational study data**
Bovis F., Kalincik T., Lublin F., Cutter G., Malpas C., Horakova D., Havrdova E. K., Trojano M., Prat A., Girard M., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th

- Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.788-790
- XXX. **Real-life outcomes of Ocrelizumab treatment from 3 multiple sclerosis centers in Turkey**
Vural E., Terzi M., Sunter G., Gunal D., Agan K., Boz C.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.751
- XXXI. **Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression**
De Brouwer E., Peeters L., Becker T., Altintas A., Soysal A., Van Wijmeersch B., Boz C., Oreja-Guevara C., Gobbi C., Solaro C., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.63-65
- XXXII. **Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up**
Boz C., Terzi M., Ozakbas S., Yuceyar N., Efendi H., Balci B. P., Turkoglu R., Karabudak R., Soysal A., Yetkin M. F., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.870
- XXXIII. **MS cohorts and treatment utilization in academic centres in the Middle East**
Moradi N., Sharmin S., Malpas C., Ozakbas S., Shaygannejad V., Alroughani R., Terzi M., Boz C., Yamout B., Turkoglu R., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.394
- XXXIV. **Aggressive form of multiple sclerosis can be predicted early after disease onset**
Malpas C. B., Manouchehrinia A., Sharmin S., Roos I., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., Eichau S., Bergamaschi R., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.605-607
- XXXV. **Multiple Sclerosis Severity Score (MSSS) helps predict relapses and recovery from disability in patients treated for multiple sclerosis in the MSBase model**
Kister I., Bacon T. E., Malpas C. B., Sharmin S., Horakova D., Havrdova E. K., Patti F., Izquierdo G., Eichau S., Ozakbas S., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.186-188
- XXXVI. **Predicting long-term sustained disability progression in multiple sclerosis**
Sharmin S., Malpas C., Horakova D., Havrdova E. K., Izquierdo G., Eichau S., Trojano M., Prat A., Girard M., Duquette P., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.119-121
- XXXVII. **Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis**
Sharmin S., Lefort M., Andersen J., Horakova D., Havrdova E. K., Alroughani R., Izquierdo G., Eichau S., Ozakbas S., Butzkueven H., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.786-788
- XXXVIII. **Determinants of therapeutic lag in relapsing multiple sclerosis**
Roos I., Frascoli F., Horakova D., Havrdova E. K., Trojano M., Izquierdo G., Eichau S., Patti F., Prat A., Girard M., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.559-561
- XXXIX. **Real-world experience with Ocrelizumab in the MSBase Registry**
Butzkueven H., Spelman T., Patti F., Ozakbas S., Eichau S., Alroughani R., Terzi M., Boz C., Grand'Maison F., Grammond P., et al.
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th

Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.539-540

- XL. **Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder**
Kunchok A., Malpas C., Nytrova P., Havrdova E., Alroughani R., TERZİ M., Yamout B., Hor J. Y., Karabudak R., BOZ C., et al.
71st Annual Meeting of the American-Academy-of-Neurology (AAN), Pennsylvania, United States Of America, 4 - 10 May 2019, vol.92
- XLI. **MULTİPL SKLEROZDA FİNGOLİMOD TEDAVİSİ SONRASI GELİŞEN GEBELİĞİN HASTALIK SEYRİNE OLAN ETKİSİ**
TERZİ M., EVİN Ö., BOZ C., ONAR M. K.
MS DAYS V, KYRENIA, 2 - 04 November 2018, pp.15
- XLII. **Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry**
Spelman T., Havrdova E., Horakova D., Izquierdo G., Kalincik T., Lugaresi A., Onofrj M., Duquette P., Girard M., Prat A., et al.
34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.31
- XLIII. **Familial multiple sclerosis: comparing demographic and clinical characteristics with sporadic form**
Eichau S., Spelman T., Izquierdo G., Laffaldano P., OrejaGuevara C., Butzkueven H., Larochele C., BOZ C., TERZİ M., Alroughani R., et al.
34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.31
- XLIV. **Determinants of disability accumulation in secondary-progressive multiple sclerosis**
Lizak N., Malpas C., Sharmin S., Havrdova E., Horakova D., Izquierdo G., Eichau S., Lugaresi A., Girard M., Duquette P., et al.
34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.30
- XLV. **RLS is an important and frequent cause of depression and anxiety in patients with MS: striking results of the 'xxRELOMS-T'xx**
SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., KÜRTÜNCÜ M., BOZ C., TUNCEL D., KARABUDAK R., et al.
34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.100
- XLVI. **RLS is an important and frequent cause of depression and anxiety in patients with MS: striking results of the 'RELOMS-T'**
Sevim S., Demirkiran M., Terzi M., Yuceyar A. N., Tasdelen B., Idiman E., Kurtuncu M., Boz C., Tuncel D., Karabudak R., et al.
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, 10 - 12 October 2018, vol.24, pp.174
- XLVII. **Variability in scoring the functional system scores of the expanded disability status scale at clinics from different countries**
Hum S., Brown R., Lapierre Y., Fellows L., Mayo N., Havrdova E. K., Horakova D., Izquierdo G., Lugaresi A., Onofrj M., et al.
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, 10 - 12 October 2018, vol.24, pp.155-156
- XLVIII. **Methylprednisolone concentration in milk and serum during and shortly after IV pulse therapy in patients with MS**
Boz C., Ozer B., Terzi M., Karahan S. Z., Sen S., Mavis M., Sarac Y.
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, 10 - 12 October 2018, vol.24, pp.978

- XLIX. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.**
Spelman T, Havrdova E. K., Horakova D., Izquierdo G., Kalincik T., Lugaresi A., Onofrj M., Duquette P., Girard M., Prat A., et al.
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, 10 - 12 October 2018, vol.24, pp.25-26
- L. Investigation of the Clinical and Morphometric Changes Before and After Acupuncture Treatment in Patients with Bell's Paralysis**
ERTEMOĞLU ÖKSÜZ C., KALAYCIOĞLU A., YILDIRIM A., UZUN Ö., KALKIŞIM Ş. N., BOZ C., ZİHNİ N. B.
1.Uluslararası Geleneksel ve Tamamlayıcı Tıp Kongresi, 19 - 22 April 2018
- LI. Let's raise the awareness of MS specialists concerning the frequency and impact of RLS in MS and consequently the life quality of patients with MS: Striking results of the 'RELOMS-T' Study**
Sevim S., Demirkiran M., TERZİ M., Yuceyar N., Tasdelen B., İDİMAN E., Kurtuncu M., BOZ C., TUNCEL D., Karabudak R., et al.
70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Chile, 21 - 27 April 2018, vol.90
- LII. A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis**
Spelman T, Havrdova E., Horakova D., Trojano M., Lugaresi A., Izquierdo G., Grammond P., Duquette P., Alroughani R., Pucci E., et al.
70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Chile, 21 - 27 April 2018, vol.90
- LIII. Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry**
Kister I., Bacon T., Shaygannejad V., Havrdova E., Alroughani R., TERZİ M., Altintas A., Hor J. Y., Al-Harbi T., BOZ C., et al.
70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Chile, 21 - 27 April 2018, vol.90
- LIV. Susac Syndrome: Clinical Features, Laboratory Testing and Treatment Responses of 3 Cases**
Ozmenoglu M., Karahan S. Z., Usta N. C., BOZ C.
10th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Ho Chi Minh City, Vietnam, 23 - 25 November 2017, vol.24, pp.421
- LV. De Novo Trigeminal Neuralgia Induced by Dalfampridine (4-aminopyridine):3 Cases**
Ozmenoglu M., BOZ C., Seker D., Horozoglu H.
10th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Ho Chi Minh City, Vietnam, 23 - 25 November 2017, vol.24, pp.379
- LVI. MULTİPL SKLEROZ'DA MORTALİTE**
TERZİ M., BOZ C., KIZILATEŞ G., ŞEN S., BEKİR Ö.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- LVII. MULTİPL SKLEROZDA FAMPRİDİNE TEDAVİSİ SONRASI TRİGEMİNAL NEVRALJİ**
TERZİ M., BOZ C., ŞENER M., BEKİR Ö., ŞEN S.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- LVIII. Multipl Skleroz artık HBS sekonder nedenleri arasında yerini almalı: Bu alanda şimdiye kadar yapılmış en geniş çaplı çalışmanın (Multipl sklerozun huzursuz bacakları-Türkiye) (RELOMS-T) çarpıcı sonuçları**
SEVİM M. S., DEMİRKİRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., KÜRTÜNCÜ M., BOZ C., TUNCEL D., KARABUDAK R., et al.
53. Ulusal Nöroloji Kongresi, Turkey, 24 - 30 November 2017
- LIX. Susac Syndrome: Clinical features, Laboratory Testing and Treatment Response of 3 cases**
ÖZMENOĞLU M., ZENGİN KARAHAN S., CAN USTA N., BOZ C.
10th Congress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis, 23 - 25 November

2017

- LX. **MS TEDAVİSİNDE TERİFLUNOMİDE VE FİNGOLUMOD'UN KARŞILAŞTIRMALI ETKİNLİK VERİLERİ**
BOZ C., ÖZAKBAŞ S., TERZİ M., TÜRKOĞLU R., SOYSAL A., TUNCER M. A., ALTINTAŞ A., EFENDİ H., AKMAN G.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017, pp.54-55
- LXI. **MULTİPL SKLERODA DİMETİL FUMARAT TEDAVİSİ GERÇEK YAŞAM VERİSİ**
TERZİ M., BOZ C., ŞEN S., GÜLER S., ÇİLİNGİR V., ŞENER M.
53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 24 - 30 November 2017, pp.229
- LXII. **MULTİPL SKLEROZ'DA NATALİZUMAB TEDAVİSİ GERÇEK YAŞAM VERİSİ**
TERZİ M., BOZ C., ÇİLİNGİR V., ŞEN S., ŞENER M., GÜLER S.
53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 24 - 30 November 2017, pp.229-230
- LXIII. **Ms Tedavisinde Kullanılan İlaçların Kesilme Oranları ve Nedenleri**
Çağlar Okumuş A., BOZ C., TERZİ M., ÖZAKBAŞ S., Türkoğlu R., Soysal A., TUNCER M. A., ALTINTAŞ A.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017
- LXIV. **MS TEDAVİSİNDE KULLANILAN İLAÇLARIN KESİLME ORANLARI VE NEDENLERİ**
ÇAĞLAR OKUMUŞ A., BOZ C., TERZİ M., ÖZAKBAŞ S., TÜRKOĞLU R., SOYSAL A., TUNCER M. A., ALTINTAŞ A.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017, pp.293
- LXV. **Orta ve Doğu Karadeniz Bölgesinde Pediyatrik ve Yetişkin Multipl Skleroz Hastalarının Demografik ve Klinik Özellikleri**
Şipal C., Akçaoğlu Y., BOZ C., TERZİ M.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017, pp.87
- LXVI. **MULTİPL SKLEROZ ARTIK HBS SEKONDER NEDENLERİ ARASINDA YERİNİ ALMALI!: BU ALANDA ŞİMDİYE KADAR YAPILMIŞ EN GENİŞ ÇAPLI ÇALIŞMANIN [MULTİPL SKLEROZUN HUZURSUZ BACAKLARI-TÜRKİYE (RELOMS-T)] ÇARPICI SONUÇLARI**
SEVİM M. S., DEMİRKIRAN D. M., TERZİ M., YÜCEYAR A. N., TAŞDELEN B., İDİMAN E., KÜRTÜNCÜ M., BOZ C., TUNCEL D., KARABUDAK R., et al.
53. ULUSAL NÖROLOJİ KONGRE, Turkey, 24 November 2017 - 30 January 2018, pp.54
- LXVII. **MS Tedavisinde Teriflunomide ve Fingolimod'un Karşılaştırmalı Etkinlik Verileri**
BOZ C., ÖZAKBAŞ S., TERZİ M., Türkoğlu R., Soysal A., TUNCER M. A., ALTINTAŞ A., EFENDİ H., AKMAN G.
53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017, pp.54
- LXVIII. **MULTİPL SKLEROZ HASTALARINDA GLATİRAMER ASETAT TEDAVİSİNİN GÜNLÜK VE HAFTADA 3 KULLANIMI İLAÇ MEMNUNİYETİ**
TERZİ M., BOZ C., BİLGE N., ÇİLİNGİR V., BEKİR Ö., BIÇAKCI D., ÇAĞLAR A., ŞEN S.
53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 24 - 30 November 2017, pp.230-231
- LXIX. **METHYLPREDNİSOLONE CONCENTRATIONS IN BREAST MILK AND SERUM IN PATIENT WITH MULTIPLE SCLEROSIS TREATED IV PULSE METHYLPREDNİSOLONE**
BOZ C., TERZİ M., KARAHAN S., ŞEN S., SARAÇ Y., MAVİŞ E.
ECTRIMS 2017, 25 - 28 October 2017
- LXX. **Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis**
Kister A., Spelman T., Patti A., duguette A., TROJANO M., Izquierdo G., Lugaresi A., Grammond P., Sola R., ferraro A., et al.
MULTIPLE SCLEROSIS JOURNAL, Paris, France, 25 - 28 October 2017
- LXXI. **Methylprednisolone concentrations in breast milk and serum in patients with multiple sclerosis treated with IV pulse methylprednisolone**
Boz C., Terzi M., Karahan S. Z., Ozbudun B., Sen S., Sarac Y., Mavis M.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.462
- LXXII. **Contribution of inflammation to disability accrual in primary progressive multiple sclerosis**
Hughes J., Jokubaitis V., Spelman T., Lugaresi A., Hupperts R., Izquierdo G., Prat A., Girard M., Duquette P., Grand'Maison F., et al.
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-

for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.399-401

LXXIII. Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis

Jokubaitis V. G., Havrdova E., Horakova D., Izquierdo G., Kalincik T., van der Walt A., Nguyen A. -, Terzi M., Alroughani R., Duquette P., et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.130-132

LXXIV. Prognostic value of MRI activity in treatment failure

Kunchok A. C., Lechner-Scott J., Granella F., Trojano M., Alroughani R., Sola P., Ferraro D., Lugaresi A., Ozakbas S., Izquierdo G., et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.988-990

LXXV. The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis

Brown J. W. L., Lugaresi A., Horakova D., Havrdova E., Jokubaitis V., Lechner-Scott J., Trojano M., Min M., Shaw C., Shuey N., et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.992-994

LXXVI. Silent lesions on MRI - shifting goal post for treatment decisions in MS

Min M., Lechner-Scott J., Spelman T., Sola P., Granella F., Butzkueven H., Alroughani R., Grammond P., Lugaresi A., Maria T., et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.393-394

LXXVII. Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis

Boz C., Ozakbas S., Terzi M., Turkoglu R., Akman G., Efendi H., Akcali A., Tuncer A., Yuceyar N., Turan O. F., et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.327-328

LXXVIII. A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS

Spelman T., Havrdova E., Horakova D., Trojano M., Lugaresi A., Izquierdo G., Grammond P., Duquette P., Alroughani R., Pucci E., et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.395-397

LXXIX. Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years

Kalincik T., Spelman T., Jokubaitis V., Horakova D., Havrdova E., Trojano M., Sola P., Ferraro D., Lugaresi A., Izquierdo G., et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.361-363

LXXX. Susac syndrome: clinical features, laboratory testing and treatment responses of 20 cases

Karahan S. Z., Boz C., Usta N. C., Saip S., Kale N., Demirkaya S., Tuncer A., Demir S., Terzi M., Celik Y., et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.90-91

LXXXI. Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study

Kalincik T, Spelman T, Jokubaitis V, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Lugaresi A, et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.325-327

LXXXII. Risk of secondary progressive multiple sclerosis: a longitudinal study

Fambiatos A, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.109-112

LXXXIII. Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis

Merkel B, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, et al.

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.71-73

LXXXIV. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis

Boz C, Terzi M, Karahan S. Z., Sen S, Sarac Y, Mavis M.

3rd Congress of the European-Academy-of-Neurology, Amsterdam, Netherlands, 01 June 2017, vol.24, pp.490

LXXXV. Pediatrik başlangıçlı multiple skleroz ile erişkin başlangıçlı multiple sklerozun klinik özelliklerinin karşılaştırılması

KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DURGUT B. D., DİLBER B., TERZİ M., BOZ C.

19. Ulusal Çocuk Nörolojisi Kongresi, Antalya, Turkey, 19 - 23 April 2017

LXXXVI. Pediatrik başlangıçlı multipl skleroz ile erişkin başlangıçlı multipl sklerozun klinik özelliklerinin karşılaştırılması.

KAMAŞAK T., CANSU A., ACAR ARSLAN E., ŞAHİN S., DİLER DURGUT B., DİLBER B., TERZİ M., BOZ C.

19. Ulusal Çocuk Nörolojisi Kongresi, Cyprus (Kkct), 19 - 23 April 2017

LXXXVII. Wernicke ensefalopatisi: olgu sunumu

GÜRSOY M., AKPINAR R., ALTUNAYOĞLU ÇAKMAK V., BOZ C., GAZİOĞLU S.

52. Ulusal Nöroloji Kongresi, Turkey, 25 November - 01 December 2016

LXXXVIII. T1-T2 radikülopatiye bağlı horner sendromu olgusu

ŞENER S., ÖZTÜRK S., GAZİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., BOZ C.

52. Ulusal Nöroloji Kongresi, Turkey, 25 November - 01 December 2016

LXXXIX. Spinal anestezi sonrası gelişen unilateral abducens sınır paralizisi

KARAMAN A., GAZİOĞLU S., GÜRSOY M., ALTUNAYOĞLU ÇAKMAK V., BOZ C.

52. Ulusal Nöroloji Kongresi, Turkey, 25 November - 01 December 2016

XC. Individual response to disease modifying therapies a global observational cohort study

Author s T Kalincik L Sobisek V Jokubaitis T Spelman D Horakova E Havrdova M Trojano G Izquierdo A Lugaresi M Girard A Prat P Duquette P Grammond P Sola R Hupperts F Grand Maison E Pucci C Boz R Alroughani V Van Pesch J Lechner Scott M Terzi R Bergamaschi G Iuliano F Granella D Spitaleri V Shaygannejad C Oreja Guevara M Slee R Ampapa F Verheul P McCombe J Olascoaga M P Amato S Vucic S Hodgkinson C Ramo S Flechter E Cristiano C Rozsa F Moore J L Sanchez Menoyo M L Saladino M Barnett H Butzkueven MSBase Study Group

Kalincik t, Sobisek l, jocubaitis v, spelman t, Dana H, Eva H, Maria T, Guile l, An L, Mm G., et al.

ECTRIMS 2016, 13 - 16 September 2016

- XCI. Comparison of 5 year treatment outcomes between alemtuzumab versus natalizumab fingolimod and interferon 1a**
Kalincik T, Brown J, Robertson R, Willis M, Scolding N, Pearson O, Ziemsen T, Hutchinson M, Jacobatis V, Spelman T, et al.
ECTRIMS 2016, 13 - 16 September 2016
- XCII. Anti inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis**
Author s J Lorscheider V Jokubaitis T Spelman G Izquierdo A Lugaresi E Havrdova D Horakova M Trojano P Duquette M Girard A Prat F Grand Maison R Hupperts P Grammond E Pucci C Boz P Sola D Spitaleri J Lechner Scott M Terzi V Van Pesch G Iuliano R Bergamaschi R Fernández Bolaños C Ramo Tello F Granella M E Rio C Oreja Guevara H Butzkueven T Kalincik MSBase Study Group
Lorscheider I, Jacobatis V, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Duquette P, BOZ C, TERZI M, et al.
ECTRIMS 2016, 14 - 16 September 2016
- XCIII. Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a**
Kalincik T, Brown J. W., Robertson N, Willis M, Scolding N, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.829-832
- XCIV. Outcomes of pregnancy in neuromyelitis optica patients: turkish multicenter study data**
Altintas A, Uygunoglu U, Terzi M, Boz C, Saip S, Koseoglu M, Kale N, Ozturk M, Demir C. F., Soysal A., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.405-406
- XCIV. Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis**
Lorscheider J, Jokubaitis V, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.367-369
- XCVI. Early disease modifying treatment delays disability accumulation in patients with pediatric onset clinically isolated syndrome suggestive of multiple sclerosis.**
Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Morra V. B., Salemi G, Patti F, Lugaresi A, Izquierdo G., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.62-63
- XCVII. Long-term disability trajectories in primary progressive MS patients - a latent class growth analysis.**
Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.44-46
- XCVIII. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod**
Fragoso Y. D., Alroughani R, Barnett M, Brooks J. B., Butzkueven H, Boz C, Granella F, Haartsen J, Havrdova E, Lugaresi A., et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.337-338
- XCIX. Individual response to disease modifying therapies: a global observational cohort study**
Kalincik T, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M., et al.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.358-360

- C. **Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer**
Spelman T, Izquierdo G, Lugaresi A, Alroughani R, Duquette P, Boz C, Fernandez Bolanos R, Pucci E, Grand'Maison F, Iuliano G, et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.600-602
- CI. **Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide**
Spelman T, Kalincik T, Trojano M, Grand'Maison F, Izquierdo G, Havrdova E, Horakova D, Lugaresi A, Duquette P, Grammond P, et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.602-603
- CII. **Real-life data from efficacy of fingolimod treatment in multiple sclerosis patients in Turkey**
Terzi M, Kurtuncu M, Eraksoy M, Karabudak R, Tuncer A, Altunrende B, Akcali A, Boz C, Sevim S, Nur Y, et al.
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.310
- CIII. **Prospectively Tracking Disease Course and Treatment Changes in Neuromyelitis Optica Using NMOBase a Global Online Registry**
Ilya Kister Tamar Bacon Vahid Shaygannejad JyhYung Hor Raed Alroughani Shannon Haas Murat Terzi Cavit Boz Javier Olascoaga Pamela McCombe Yara Fragoso Alessandra Lugaresi Patrizia Sola Steve Vucic Eugenio Pucci Talal Al Harbi Seyed Aidin Sajedi Juan Ignacio Rojas Liliana Patrucco Edgardo Cristiano Jose Alberto Suarez Magdalini Tsolaki Bruce Taylor Gerardo Iuliano Paschalis Devranis Mark Marriott Helmut Butzkueven
Kister I, bocan t, Shaygannejad v, Yung Hor j, Alroughani r, Shannon h, TERZİ M, BOZ C, Olascoaga o, Butzkueven h.
aan2016, 12 - 18 April 2016
- CIV. **Prospectively tracking disease course and treatment changes in Neuromyelitis Optica using NMOBase, a global online registry.**
Kister I, Bacon T, Shaygannejad V, Hor J. Y., Alroughani R, Haas S, Terzi M, Boz C, Olascoaga J, McCombe P, et al.
68th Annual Meeting of the American-Academy-of-Neurology (AAN), Vancouver, Canada, 15 - 21 April 2016, vol.86
- CV. **Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.**
Butzkueven H, Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, et al.
8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul, South Korea, 19 - 21 November 2015, vol.22, pp.418-419
- CVI. **MS te yeni fenotipik patolojik ve klinik sınıflama**
BOZ C.
Ulusal Nöroloji kongresi, Turkey, 29 November - 01 December 2015
- CVII. **Comparative efficacy of first-line natalizumab versus IFN β or glatiramer acetate in relapsing MS**
Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.258-259
- CVIII. **Effect of relapse phenotype on the accumulation of disability in relapsing-remitting multiple sclerosis**
Stewart T, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS),

Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.726-728

- CIX. Defining secondary progressive multiple sclerosis**
Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P., et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.798-800
- CX. 10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort**
Jokubaitis V. G., Spelman T., Kalincik T., Travaglini D., Paolicelli D., Duquette P., Girard M., Prat A., Havrdova E., Horakova D., et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.100-102
- CXI. Comparison of efficacy and persistence of first line fingolimod vs interferon-beta/glatiramer in the presence of prior disease activity**
Spelman T, Izquierdo G, Alroughani R, Fernandez Bolaos R, Havrdova E, Horaova D, Oreja-Guevara C, Lechner-Scott J, Slee M, Barnett M., et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.237-238
- CXII. Lack of association between pulse steroid therapy and bone mineral density in patients with multiple sclerosis**
KARAHAN S. C., BOZ C., USTA N. C., KILIC S., Ozmenoglu M., Altunayoglu V., GAZİOĞLU S.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.773
- CXIII. Immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis**
Lizak N., Lugaresi A., Alroughani R., Lechner-Scott J., Slee M., Havrdova E., Horakova D., Trojano M., Izquierdo G., Duquette P., et al.
31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.308-310
- CXIV. Evaluation of common criteria of progression of disability in a large observational cohort**
Kalincik T., Jokubaitis V., Spelman T., Horakova D., Havrdova E., Trojano M., Izquierdo G., Girard M., Duquette P., Lugaresi A., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.62-63
- CXV. Predictors of disability accrual in multiple sclerosis patients on first-line therapy**
Spelman T, Jokubaitis V, Izquierdo G, Duquette P, Grand'Maison F, Grammond P, Hupperts R, Havrdova E, Oreja-Guevara C, Alroughani R., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.405
- CXVI. Seasonal variation of relapse rate in MS is latitude-dependent**
Spelman T, Gray O, Trojano M, Petersen T, Izquierdo G, Lugaresi A, Hupperts R, Bergamaschi R, Duquette P, Grammond P., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.218-219
- CXVII. Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis**
Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., Izquierdo G., Rozsa C., Grammond P., Alroughani R., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.195-196
- CXVIII. Neuromyelitis optica and neuromyelitis optica spectrum disorder patients in Turkish cohort: demographic, clinical, laboratory and radiological features**
Altintas A., Karabudak R., Balci B. P., Terzi M., Soysal A., Saip S., Kurne A. T., Uygunoglu U., Nalbantoglu M., Celik G. G.,

et al.

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.348-349

- CXIX. **Independent predictors of time to relapse after CIS in high-risk patients**
Spelman T, Meyniel C, Trojano M, Lugaresi A, Izquierdo G, Grand'Maison F, Boz C, Alroughani R, Havrdova E, Iuliano G., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.54
- CXX. **Comparison of fingolimod versus interferon beta/glatiramer acetate as second-line therapy in active multiple sclerosis**
He A, Spelman T, Jokubaitis V, Lugaresi A, Izquierdo G, Trojano M, Grammond P, Lechner-Scott J, Duquette P, Girard M., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.193
- CXXI. **NMOBase is a Web-based, global observational registry for an 'orphan' disorder: neuromyelitis optica**
Kister I, Bacon T, Alroughani R, Boz C, Cristiano E, Iuliano G, Marriott M, Olascoaga J, Pucci E, Rojas J. I., et al.
Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.165
- CXXII. **Rekürrenslerle giden ADEM Guillain Barre Sendromu birlikteliği: Olgu Sunumu**
ŞAHİN S., KAMAŞAK T., Baba Ö., CANSU A., BOZ C.
16. Ulusal Çocuk Nöroloji Kongresi, Turkey, 22 - 27 June 2014
- CXXIII. **Head-to-head Comparisons of Interferon Beta and Glatiramer Acetate in Clinical Practice**
Butzkueven H, Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P, Lugaresi A, Oreja-Guevara C, Grand-Maison F., et al.
6th Congress of the Pan-Asian-Committee-on-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Kyoto, Japan, 6 - 08 November 2013, vol.20, pp.927
- CXXIV. **Factors associated with early hospital arrival in acute ischemic stroke patients**
Koksal E. K., Gazioglu S., Boz C., Can G., Alioglu Z.
Joint Congress of European Neurology, İstanbul, Turkey, 31 May - 03 June 2014, vol.261
- CXXV. **Factors associated with early hospital arrival in acute ischemic stroke patients**
Koksal E. K., Gazioglu S., Boz C., Can G., Alioglu Z.
Joint Congress of European Neurology, İstanbul, Turkey, 31 May - 03 June 2014, vol.21, pp.353
- CXXVI. **Multipl Skleroz hastalarında kişilik özellikleri ve klinik özelliklerle ilişkisi**
GAZİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., ÖZKORUMAK KARAGÜZEL E., CAN USTA N., BOZ C.
49. Ulusal Nöroloji Kongresi, Trabzon, Turkey, 15 - 21 November 2013
- CXXVII. **Multipl Skleroz hastalarında kişilik özellikleri ve klinik özelliklerle ilişkisi**
GAZİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., ÖZKORUMAK KARAGÜZEL E., USTA N. C., BOZ C.
49. Ulusal Nöroloji Kongresi, Antalya, Turkey, 15 - 21 November 2013, pp.108
- CXXVIII. **Huzursuz bacaklar sendromlu hastaların mizaç ve karakter özellikleri**
ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S., ÖZKORUMAK KARAGÜZEL E., USTA N. C., TOPBAŞ M., BOZ C.
14. Ulusal Uyku Tıbbı Kongresi, Muğla, Turkey, 6 - 10 October 2013, pp.9
- CXXIX. **Head-to-head comparisons of preparations of interferon beta and glatiramer acetate: a series of quasi-randomised MSBase trials**
Kalincik T, Trojano M, Izquierdo G, Duquette P, Girard M, Grammond P, Lugaresi A, Oreja-Guevara C, Grand'Maison F, Giuliani G., et al.
29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.569-571
- CXXX. **Symptomatology of multiple sclerosis relapses varies in relation to demographic and clinical factors**
Kalincik T, Buzzard K, Trojano M, Duquette P, Girard M, Izquierdo G, Grammond P, Lugaresi A, Petersen T, Hupperts R., et al.
29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.112-114
- CXXXI. **Relapse incidence in women and men throughout the course of multiple sclerosis: an MSBase cohort**

study

Kalincik T., Vivek V., Jokubaitis V., Lechner-Scott J., Trojano M., Izquierdo G., Lugaresi A., Grand'Maison F., Hupperts R., Oreja-Guevara C., et al.

29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.28-30

CXXXII. Predictors of 12-month confirmed disability progression after onset of clinically isolated syndrome (CIS) suggestive of multiple sclerosis

Jokubaitis V. G., Spelman T., Trojano M., Izquierdo G., Grand'Maison F., Duquette P., Girard M., Lugaresi A., Grammond P., Hupperts R., et al.

29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.13-15

CXXXIII. Defining secondary progressive multiple sclerosis: is it possible to diagnose early?

Spelman T., Trojano M., Duquette P., Izquierdo G., Lugaresi A., Grammond P., Grand'Maison F., Hupperts R., Bergamaschi R., Giuliani G., et al.

29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.38

CXXXIV. Does switching to fingolimod from natalizumab result in short-term relapse exacerbation?

Jokubaitis V. G., Li V., Kalincik T., Izquierdo G., Hodgkinson S., Alroughani R., Lechner-Scott J., Lugaresi A., Duquette P., Girard M., et al.

29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.55-56

CXXXV. Clinical And Radiological Characteristics Of Tumefactive Demyelinating Lesions: Follow-up Study

Altintas A., Petek B., Isik N., Terzi M., Bolukbasi F., Tavsanli M., Saip S., Boz C., Aydin T., Arici-Duz O., et al.

5th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Beijing, China, 13 - 15 September 2012, vol.19, pp.656

CXXXVI. EXPOSURE TO INTERFERON-beta THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS

Hughes S., Spelman T., Gray O., Boz C., Trojano M., Zwanikken C., Lugaresi A., Izquierdo J., Duquette P., Girard M., et al.

Annual Meeting of the Association-of-British-Neurologists, Brighton, England, 28 - 31 May 2012, vol.83

CXXXVII. PREDICTORS OF POSTPARTUM RELAPSES IN WOMEN WITH MULTIPLE SCLEROSIS: RESULTS FROM THE MSBASE REGISTRY

Hughes S. E., Spelman T., Gray O. M., Boz C., Trojano M., McDonnell G. V., Hawkins S. A., Kee F., Butzkueven H.

Annual Meeting of the Association-of-British-Neurologists, Brighton, England, 28 - 31 May 2012, vol.83

CXXXVIII. Risk factors of reduced bone mass in patients with multiple sclerosis

Boz C., Karahan S. Z.

28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon, France, 10 - 13 October 2012, vol.18, pp.249

CXXXIX. Seasonal variation of relapse rate and ultraviolet radiation levels are sinusoidal and their phase-shifted relationship is latitude-dependent

Spelman T., Gray O., Trojano M., Lugaresi A., Izquierdo G., Zwanikken C., Duquette P., Grand'Maison F., Shaygannejad V., Grammond P., et al.

28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon, France, 10 - 13 October 2012, vol.18, pp.83-84

CXL. Male MS patients fare worse!

Ribbons K. A., McElduff P., Vetere S., Boz C., Trojano M., Zwanikken C., Lugaresi A., Izquierdo G., Duquette P., Girard M., et al.

28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon, France, 10 - 13 October 2012, vol.18, pp.79-80

CXLI. Multiple sklerozda huzursuz bacaklar sendromu

ALTUNAYOĞLU ÇAKMAK V., CANATAN S., GAZİOĞLU S., BOZ C.

47. Ulusal Nöroloji Kongresi, Antalya, Turkey, 25 November - 01 December 2011, pp.68
- CXLII. **Multiple skleroz hastalarında uykusuzluk ve özellikleri**
ALTUNAYOĞLU ÇAKMAK V., CANATAN S., GAZİOĞLU S., BOZ C.
47. Ulusal Nöroloji Kongresi, Antalya, Turkey, 25 November - 01 December 2011, pp.67
- CXLIII. **Predictors of Confirmed Disability Progression after a First Demyelinating Event**
Butzkueven H., Spelman T., Izquierdo G., Grand-Maison F., Trojano M., Zwanikken C., Oreja-Guevara C., Lugaresi A., Petersen T., Boz C., et al.
63rd AAN Annual Meeting, Hawaii, United States Of America, 9 - 16 April 2011, vol.76
- CXLIV. **Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a prospective, multicentre study**
Eraksoy M., Akman-Demir G., Agan K., Gunal D., Us O., Saip S., Demirci N. O., Tutuncu M., Turan O. F., Taskapilioglu O., et al.
19th World Congress of Neurology, Bangkok, Thailand, 24 - 30 October 2009, vol.285
- CXLV. **Onset of relapses in multiple sclerosis: the effect of seasonal change in both the northern and southern hemisphere**
Gray O., Jolley D., Gibson K., Trojano M., Zwanikken C., Grand'Maison F., Duquette P., Izquierdo G., Grammond P., Bergamaschi R., et al.
25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Düsseldorf, Germany, 9 - 12 September 2009, vol.15
- CXLVI. **Temporal Variation of Onset of Relapses in Multiple Sclerosis: Results from the Northern and Southern Hemispheres in the MSBase Registry**
Gray O. M., Jolley D., Zwanikken C., Trojano M., Grand-Maison F., Duquette P., Grammond P., Bergamaschi R., Giuliani G., Taffi R., et al.
61st Annual Meeting of American-Academy-of-Neurology, Washington, United States Of America, 28 - 29 April 2009, vol.72
- CXLVII. **Temporal variation of onset of relapses in multiple sclerosis is not seasonal: results from the MSBase registry**
Gray O. M., Jolley D., Zwanikken C., Trojano M., Grand'Maison F., Duquette P., Grammond P., Bergamaschi R., Giuliani G., Taffi R., et al.
1st Congress of Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Kuala-Lumpur, Malaysia, 21 - 22 November 2008, vol.15, pp.137-138
- CXLVIII. **The Multiple Sclerosis Severity Score (MSSS) re-examined: EDSS rank stability in the MSBase dataset increases 5 years after onset of multiple sclerosis**
Gray O. M., Zwanikken C., Trojano M., Grand'Maison F., Duquette P., Grammond P., Bergamaschi R., Giuliani G., Taffi R., Hupperts R. M. M., et al.
1st Congress of Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Kuala-Lumpur, Malaysia, 21 - 22 November 2008, vol.15, pp.140
- CXLIX. **The Multiple Sclerosis Severity Score re-examined: Expanded Disability Status Scale rank stability in the MSBase dataset increases five years after onset of multiple sclerosis**
Butzkueven H., Jolley D., Trojano M., Zwanikken C., Maison F. G., Duquette P., Grammond P., Bergamaschi R., Giuliani G., Timmermans B., et al.
13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, Montreal, Canada, 17 - 20 September 2008, vol.14
- CL. **Tumefactive demyelinating disease is immunologically different from multiple sclerosis**
Boz C., Gazioglu S., Terzi M.
23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/12th Annual Conference of Rehabilitation in MS, Prague, Czech Republic, 11 - 14 October 2007, vol.13
- CLI. **Reduced effectiveness of long-term interferon beta treatment on relapses in neutralising antibody-positive multiple sclerosis patients: a Canadian MS clinic-based study**
Oger J., Boz C., Devonshire V., Hashimoto S., Hooge J., Kastrukoff L., Smyth P., Traboulsee A.

23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/12th Annual Conference of Rehabilitation in MS, Prague, Czech Republic, 11 - 14 October 2007, vol.13

- CLII. **Trial-defined disease progression in multiple sclerosis is a poor measure of permanent disability progression.**
Butzkueven H., Mechat S., Hoffmann M. W., Arruda W., Boz C., Bacile E., Caride A., Chapman J., Charest S., Cristiano E., et al.
59th Annual Meeting of the American-Academy-of-Neurology, Massachusetts, United States Of America, 28 April - 05 May 2007, vol.68
- CLIII. **Bilateral talamik infaktlarda klinik ve radyolojik bulgular**
GAZİOĞLU S., BOZ C., ALTUNAYOĞLU ÇAKMAK V.
42. Ulusal Nöroloji Kongresi, Antalya, Turkey, 12 - 17 November 2006, pp.169
- CLIV. **Is the current trial definition of confirmed disability progression in multiple sclerosis an accurate measure of permanent disease progression?**
Butzkueven H., Mechat S., Hoffmann M., Arruda W. O., Bacile E., Boz C., Caride A., Chapman J., Charest S., Cristiano E., et al.
22nd Congress of the European-Committee-for-the-Treatment-and-Resarch-in-Multiple-Sclerosis, Madrid, Spain, 27 - 30 September 2006, vol.12
- CLV. **The MSBase Global Web Registry: joining independent local patient databases for multi-centre research**
Butzkueven H., Arruda W., Boz C., Chapman J., Cristiano E., Fiol M., Giuliani G., Grammond P., Grand'Maison F., Hoffmann M., et al.
18th World Congress of Neurology, Sydney, Australia, 5 - 11 November 2005, vol.238
- CLVI. **Economic impact of primary headaches in Turkey: a university hospital-based study, part II**
Karly N., Zarifoglu M., Ertas M., Saip S., Ozturk V., Bycakcy P., Boz C., Selcuki D., Oduzhanodlu A., Neyal M., et al.
22nd Congress of the International-Headache-Society, Kyoto, Japan, 9 - 12 October 2005, vol.25, pp.951
- CLVII. **The MSBase Global Registry: a web platform for collaborative multiple sclerosis outcomes research**
Butzkueven H., Arruda W., Boz C., Chapman J., Cristiano E., Deri N., Fiol M., Giuliani G., Grammond P., Grand'Maison F., et al.
21st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/10th Annual Meeting of Rehabilitation in MS, Thessaloniki, Greece, 28 September - 01 October 2005, vol.11
- CLVIII. **Neutralising antibodies reduce the effect of interferon on relapse rate: the British Columbia experience, Canada**
Boz C., Gibbs E., Grossberg S., Oger J.
21st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/10th Annual Meeting of Rehabilitation in MS, Thessaloniki, Greece, 28 September - 01 October 2005, vol.11
- CLIX. **Human herpesvirus 6-7-8 and Chlamydia pneumoniae infection in multiple sclerosis**
Boz C., Altunayoglu V., Acar O., Gazioglu S., Ozmenoglu M.
21st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/10th Annual Meeting of Rehabilitation in MS, Thessaloniki, Greece, 28 September - 01 October 2005, vol.11
- CLX. **Multipl skleroz hastalarında serum ve BOS matriks metalloproteinaz 9 ve matriks metalloproteinaz doku inhibitörler 1 seviyelerinin interferon beta 1 tedavisi öncesi ve sonrası değerlendirilmesi**
BOZ C., ÖZMENOĞLU M., KILINÇ K., ÖREM A., VELİOĞLU S., ALİOĞLU Z., ALTUNAYOĞLU ÇAKMAK V.
40. Ulusal Nöroloji Kongresi, Trabzon, Turkey, 29 September - 03 October 2004
- CLXI. **Multipl sklerozlu hastada viral enfeksiyonların kanıtları**
ACAR Ö., ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZMENOĞLU M., ALİOĞLU Z., VELİOĞLU S.
40. Ulusal Nöroloji Kongresi,, Antalya, Turkey, 29 September - 03 October 2004, pp.203
- CLXII. **Multipl skleroz hastalarında serum ve BOS matriks metalloproteinaz- 9 ve matriks metalloproteinaz doku inhibitörler-1 seviyelerinin interferon beta-1 tedavisi öncesi ve sonrası degerlendirilmesi**
BOZ C., ÖZMENOĞLU M., KILINC K., ÖREM A., VELİOĞLU S., ALİOĞLU Z., ALTUNAYOĞLU ÇAKMAK V.
40. Ulusal Nöroloji Kongresi, Antalya, Turkey, 29 September - 03 October 2004, pp.317
- CLXIII. **NORMAL POPÜLASYONDA İNSAN HERPES VİRUS 6 VE 7 DNA SIKLIĞI**

SANCAKTAR M., BOZ C., KAKLIKKAYA N., TOSUN İ., BURUK C. K., YAZICI Y., AYDIN F.

3.ULUSAL MOLEKÜLER VE TANISAL MİKROBİYOLOJİ KONGRESİ, Ankara, Turkey, 28 June 2004

CLXIV. **Doğu Karadeniz bölgesindeki multipl skleroz hastalarının klinik ve demografik özellikleri**

ACAR Ö., BOZ C., ALTUNAYOĞLU ÇAKMAK V., ÖZMENOĞLU M.

39. Ulusal Nöroloji Kongresi, Trabzon, Turkey, 22 - 26 October 2003

CLXV. **Ulseratif kolitle ilişkili hemorajik infarkt vaka sunumu**

ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZGÜR S., ÖZMENOĞLU M.

39. Ulusal Nöroloji Kongresi, Trabzon, Turkey, 22 - 26 October 2003

CLXVI. **Ağırılık kaldırma egzersizi sonrası gelişen spinal aksesöri sinir hasarı**

ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZMENOĞLU M.

39.Ulusal Nöroloji Kongresi, Trabzon, Turkey, 22 - 26 October 2003

CLXVII. **Doğu Karadeniz bölgesindeki multipl skleroz hastalarının klinik ve demografik özellikleri**

ACAR Ö., BOZ C., ALTUNAYOĞLU ÇAKMAK V., ÖZMENOĞLU M.

39.Ulusal Nöroloji Kongresi, Antalya, Turkey, 22 - 26 October 2003, pp.440-441

CLXVIII. **Ulseratif kolitle ilişkili hemorajik infarkt vaka sunumu**

ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZGÜR S., ÖZMENOĞLU M.

39.Ulusal Nöroloji Kongresi, Antalya, Turkey, 22 - 26 October 2003, pp.336-337

CLXIX. **Ağırılık kaldırma egzersizi sonrası gelişen spinal aksesöri sinir hasarı**

ALTUNAYOĞLU ÇAKMAK V., BOZ C., ÖZMENOĞLU M.

39.Ulusal Nöroloji Kongresi, Antalya, Turkey, 22 - 26 October 2003, pp.369

CLXX. **The efficacy and safety of dipyrone (NOVALGIN) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multicenter pilot study**

Tulunay F., Ergun H., Gulmez S., Ozbenli T., Ozmenoglu M., Boz C., Erdemoglu A., Varlikbas A., Goksan B., Inan L.

11th Congress of the International-Headache-Society, Rome, Italy, 12 - 16 September 2003, vol.23, pp.578

CLXXI. **Lokal soğuk uygulamasının sempatetik deri yanıtı toparlanma eğrisine etkisi**

BOZ C., ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S., ÖZMENOĞLU M.

20. Ulusal Klinik Nörofizyoloji EEG-EMG Kongresi, Gaziantep, Turkey, 27 - 31 May 2003

CLXXII. **Lokal soğuk uygulamasının sempatetik deri yanıtı toparlanma eğrisine etkisi**

BOZ C., ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S., ÖZMENOĞLU M.

20. Ulusal Klinik Nörofizyoloji EEG-EMG Kongresi, Gaziantep, Turkey, 27 - 31 May 2003, pp.29

CLXXIII. **Mermer beyin hastalığı serebral kalsifikasyon renal tübüler asidoz osteopetrosis**

BOZ C., ALTUNAYOĞLU ÇAKMAK V., KAYNAR R. K., ALİOĞLU Z., VELİOĞLU S., ÖZMENOĞLU M.

38. Ulusal Nöroloji Kongresi, Trabzon, Turkey, 19 - 23 October 2002

CLXXIV. **Mermer beyin hastalığı serebral kalsifikasyon, renal tübüler asidoz, osteopetrosis.**

BOZ C., ALTUNAYOĞLU ÇAKMAK V., KAYNAR R. K., ALİOĞLU Z., VELİOĞLU S., ÖZMENOĞLU M.

38. Ulusal Nöroloji Kongresi, Antalya, Turkey, 19 - 23 October 2002, pp.107

CLXXV. **Karpal tünel sendromunda ısının sinir ileti parametrelerine etkisi**

BOZ C., ALTUNAYOĞLU ÇAKMAK V., ÖZMENOĞLU M., TAN M.

19. Ulusal Klinik Nörofizyoloji EEG-EMG Kongresi, Trabzon, Turkey, 8 - 13 June 2002, pp.205

CLXXVI. **El ve vücut ölçüklerinin karpal tünel sendromu ile ilişkisi**

BOZ C., ALTUNAYOĞLU ÇAKMAK V., VELİOĞLU S., ÖZMENOĞLU M., TAN M.

19. Ulusal Klinik Nörofizyoloji EEG-EMG Kongresi, Trabzon, Turkey, 08 June 2002 - 13 June 2003, pp.206

Other Publications

I. **Local cold effect on the excitability recovery curve of the sympathetic skin response**

BOZ C., ÖZMENOĞLU M., ALİOĞLU Z., VELİOĞLU S., ALTUNAYOĞLU ÇAKMAK V., GAZİOĞLU S.

Other, pp.497-501, 2004

Supported Projects

KALAYCIOĞLU A., ERTEMOĞLU ÖKSÜZ C., BOZ C., KALKIŞIM Ş. N., UZUN Ö., YILDIRIM A., Project Supported by Higher Education Institutions, Bell Paralizili Hastalarda Akupunktur Tedavisi Öncesi ve Sonrası Elektrofizyolojik ve Morfometrik Ölçümlerin Değerlendirilmesi, 2016 - 2017

Metrics

Publication: 366

Citation (WoS): 4850

Citation (Scopus): 5503

H-Index (WoS): 34

H-Index (Scopus): 35

Non Academic Experience

Türk Nöroloji Derneği

University of British Columbia, MS Clinic, Vancouver

University of British Columbia, MS Clinic, Vancouver